From HandWiki
Short description: Group of diseases involving abnormal cell growth and spread
Other namesMalignant tumor, malignant neoplasm
Tumor Mesothelioma2 legend.jpg
A coronal CT scan showing a malignant mesothelioma
Legend: → tumor ←, ✱ central pleural effusion, 1 & 3 lungs, 2 spine, 4 ribs, 5 aorta, 6 spleen, 7 & 8 kidneys, 9 liver
SymptomsLump, abnormal bleeding, prolonged cough, unexplained weight loss, change in bowel movements[1]
Risk factorsExposure to carcinogens, tobacco, obesity, poor diet, lack of physical activity, excessive alcohol, certain infections[2][3]
TreatmentRadiation therapy, surgery, chemotherapy, targeted therapy[2][4]
PrognosisAverage five-year survival 66% (USA)[5]
Frequency24 million annually (2019)[6]
Deaths10 million annually (2019)[6]

Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.[2][7] These contrast with benign tumors, which do not spread.[7] Possible signs and symptoms include a lump, abnormal bleeding, prolonged cough, unexplained weight loss, and a change in bowel movements.[1] While these symptoms may indicate cancer, they can also have other causes.[1] Over 100 types of cancers affect humans.[7]

Tobacco use is the cause of about 22% of cancer deaths.[2] Another 10% are due to obesity, poor diet, lack of physical activity or excessive alcohol consumption.[2][8][9] Other factors include certain infections, exposure to ionizing radiation, and environmental pollutants.[3] Infection with specific viruses, bacteria and parasites is an environmental factor causing approximately 16-18% of cancers worldwide.[10] These infectious agents include Helicobacter pylori, hepatitis B, hepatitis C, human papillomavirus infection, Epstein–Barr virus, Human T-lymphotropic virus 1, Kaposi's sarcoma-associated herpesvirus and Merkel cell polyomavirus. Human immunodeficiency virus (HIV) does not directly cause cancer but it causes immune deficiency that can magnify the risk due to other infections, sometimes up to several thousand fold (in the case of Kaposi's sarcoma). Importantly, vaccination against hepatitis B and human papillomavirus have been shown to nearly eliminate risk of cancers caused by these viruses in persons successfully vaccinated prior to infection.

These environmental factors act, at least partly, by changing the genes of a cell.[11] Typically, many genetic changes are required before cancer develops.[11] Approximately 5–10% of cancers are due to inherited genetic defects.[12] Cancer can be detected by certain signs and symptoms or screening tests.[2] It is then typically further investigated by medical imaging and confirmed by biopsy.[13]

The risk of developing certain cancers can be reduced by not smoking, maintaining a healthy weight, limiting alcohol intake, eating plenty of vegetables, fruits, and whole grains, vaccination against certain infectious diseases, limiting consumption of processed meat and red meat, and limiting exposure to direct sunlight.[14][15] Early detection through screening is useful for cervical and colorectal cancer.[16] The benefits of screening for breast cancer are controversial.[16][17] Cancer is often treated with some combination of radiation therapy, surgery, chemotherapy and targeted therapy.[2][4] Pain and symptom management are an important part of care.[2] Palliative care is particularly important in people with advanced disease.[2] The chance of survival depends on the type of cancer and extent of disease at the start of treatment.[11] In children under 15 at diagnosis, the five-year survival rate in the developed world is on average 80%.[18] For cancer in the United States, the average five-year survival rate is 66% for all ages.[5]

In 2015, about 90.5 million people worldwide had cancer.[19] In 2019, annual cancer cases grew by 23.6 million people, and there were 10 million deaths worldwide, representing over the previous decade increases of 26% and 21%, respectively.[6][20]

The most common types of cancer in males are lung cancer, prostate cancer, colorectal cancer, and stomach cancer.[21][22] In females, the most common types are breast cancer, colorectal cancer, lung cancer, and cervical cancer.[11][22] If skin cancer other than melanoma were included in total new cancer cases each year, it would account for around 40% of cases.[23][24] In children, acute lymphoblastic leukemia and brain tumors are most common, except in Africa, where non-Hodgkin lymphoma occurs more often.[18] In 2012, about 165,000 children under 15 years of age were diagnosed with cancer.[21] The risk of cancer increases significantly with age, and many cancers occur more commonly in developed countries.[11] Rates are increasing as more people live to an old age and as lifestyle changes occur in the developing world.[25] The global total economic costs of cancer were estimated at United States dollar 1.16 trillion (equivalent to $1.36 trillion in 2019) per year (As of 2010).[26]


Etymology and definitions

The word comes from the ancient Greek καρκίνος, meaning 'crab' and 'tumor'. Greek physicians Hippocrates and Galen, among others, noted the similarity of crabs to some tumors with swollen veins. The word was introduced in English in the modern medical sense around 1600.[27]

Cancers comprise a large family of diseases that involve abnormal cell growth with the potential to invade or spread to other parts of the body.[2][7] They form a subset of neoplasms. A neoplasm or tumor is a group of cells that have undergone unregulated growth and will often form a mass or lump, but may be distributed diffusely.[28][29]

All tumor cells show the six hallmarks of cancer. These characteristics are required to produce a malignant tumor. They include:[30]

The progression from normal cells to cells that can form a detectable mass to cancer involves multiple steps known as malignant progression.[30][31]

Signs and symptoms

Main page: Medicine:Cancer signs and symptoms
Symptoms of cancer metastasis depend on the location of the tumor.

When cancer begins, it produces no symptoms. Signs and symptoms appear as the mass grows or ulcerates. The findings that result depend on cancer's type and location. Few symptoms are specific. Many frequently occur in individuals who have other conditions. Cancer can be difficult to diagnose and can be considered a "great imitator."[32]

People may become anxious or depressed post-diagnosis. The risk of suicide in people with cancer is approximately double.[33]

Local symptoms

Local symptoms may occur due to the mass of the tumor or its ulceration. For example, mass effects from lung cancer can block the bronchus resulting in cough or pneumonia; esophageal cancer can cause narrowing of the esophagus, making it difficult or painful to swallow; and colorectal cancer may lead to narrowing or blockages in the bowel, affecting bowel habits. Masses in breasts or testicles may produce observable lumps. Ulceration can cause bleeding that can lead to symptoms such as coughing up blood (lung cancer), anemia or rectal bleeding (colon cancer), blood in the urine (bladder cancer), or abnormal vaginal bleeding (endometrial or cervical cancer). Although localized pain may occur in advanced cancer, the initial tumor is usually painless. Some cancers can cause a buildup of fluid within the chest or abdomen.[32]

Systemic symptoms

Systemic symptoms may occur due to the body's response to the cancer. This may include fatigue, unintentional weight loss, or skin changes.[34] Some cancers can cause a systemic inflammatory state that leads to ongoing muscle loss and weakness, known as cachexia.[35]

Some cancers, such as Hodgkin's disease, leukemias, and liver or kidney cancers, can cause a persistent fever.[32]

Shortness of breath, called dyspnea, is a common symptom of cancer and its treatment. The causes of cancer-related dyspnea can include tumors in or around the lung, blocked airways, fluid in the lungs, pneumonia, or treatment reactions including an allergic response.[36] Treatment for dyspnea in patients with advanced cancer can include fans, bilevel ventilation, acupressure/reflexology and multicomponent nonpharmacological interventions.[37]

Some systemic symptoms of cancer are caused by hormones or other molecules produced by the tumor, known as paraneoplastic syndromes. Common paraneoplastic syndromes include hypercalcemia, which can cause altered mental state, constipation and dehydration, or hyponatremia, which can also cause altered mental status, vomiting, headaches, or seizures.[38]


Main page: Medicine:Metastasis

Metastasis is the spread of cancer to other locations in the body. The dispersed tumors are called metastatic tumors, while the original is called the primary tumor. Almost all cancers can metastasize.[39] Most cancer deaths are due to cancer that has metastasized.[40]

Metastasis is common in the late stages of cancer and it can occur via the blood or the lymphatic system or both. The typical steps in metastasis are local invasion, intravasation into the blood or lymph, circulation through the body, extravasation into the new tissue, proliferation and angiogenesis. Different types of cancers tend to metastasize to particular organs, but overall the most common places for metastases to occur are the lungs, liver, brain, and the bones.[39]

While some cancers can be cured if detected early, metastatic cancer is more difficult to treat and control. Nevertheless, some recent treatments are demonstrating encouraging results.[41]


Main page: Medicine:Causes of cancer
The GHS Hazard pictogram for carcinogenic substances
Share of cancer deaths attributed to tobacco in 2016.[42]

The majority of cancers, some 90–95% of cases, are due to genetic mutations from environmental and lifestyle factors.[3] The remaining 5–10% are due to inherited genetics.[3] Environmental refers to any cause that is not inherited, such as lifestyle, economic, and behavioral factors and not merely pollution.[43] Common environmental factors that contribute to cancer death include tobacco use (25–30%), diet and obesity (30–35%), infections (15–20%), radiation (both ionizing and non-ionizing, up to 10%), lack of physical activity, and pollution.[3][44] Psychological stress does not appear to be a risk factor for the onset of cancer,[45][46] though it may worsen outcomes in those who already have cancer.[45]

Environmental or lifestyle factors that caused cancer to develop in an individual can be identified by analyzing mutational signatures from genomic sequencing of tumor DNA. For example, this can reveal if lung cancer was caused by tobacco smoke, if skin cancer was caused by UV radiation, or if secondary cancers were caused by previous chemotherapy treatment.[47]

Cancer is generally not a transmissible disease.[48] Except for rare transmissions that occur with pregnancies and occasional organ donors. However, transmissible infectious diseases such as hepatitis B, Epstein-Barr virus, Human Papilloma Virus and HIV, can contribute to the development of cancer.


The incidence of lung cancer is highly correlated with smoking.

Exposure to particular substances have been linked to specific types of cancer. These substances are called carcinogens.

Tobacco smoke, for example, causes 90% of lung cancer.[49] Tobacco use can cause cancer throughout the body including in the mouth and throat, larynx, esophagus, stomach, bladder, kidney, cervix, colon/rectum, liver and pancreas.[50][51] Tobacco smoke contains over fifty known carcinogens, including nitrosamines and polycyclic aromatic hydrocarbons.[52]

Tobacco is responsible for about one in five cancer deaths worldwide[52] and about one in three in the developed world.[53] Lung cancer death rates in the United States have mirrored smoking patterns, with increases in smoking followed by dramatic increases in lung cancer death rates and, more recently, decreases in smoking rates since the 1950s followed by decreases in lung cancer death rates in men since 1990.[54][55]

In Western Europe, 10% of cancers in males and 3% of cancers in females are attributed to alcohol exposure, especially liver and digestive tract cancers.[56] Cancer from work-related substance exposures may cause between 2 and 20% of cases,[57] causing at least 200,000 deaths.[58] Cancers such as lung cancer and mesothelioma can come from inhaling tobacco smoke or asbestos fibers, or leukemia from exposure to benzene.[58]

Exposure to perfluorooctanoic acid (PFOA), which is predominantly used in the production of Teflon, is known to cause two kinds of cancer.[59][60]

Chemotherapy drugs such as platinum-based compounds are carcinogens that increase the risk of secondary cancers[47]

Azathioprine, an immunosuppressive medication, is a carcinogen that can cause primary tumors to develop.[47]

Diet and exercise

Main page: Medicine:Diet and cancer

Diet, physical inactivity, and obesity are related to up to 30–35% of cancer deaths.[3][61] In the United States, excess body weight is associated with the development of many types of cancer and is a factor in 14–20% of cancer deaths.[61] A UK study including data on over 5 million people showed higher body mass index to be related to at least 10 types of cancer and responsible for around 12,000 cases each year in that country.[62] Physical inactivity is believed to contribute to cancer risk, not only through its effect on body weight but also through negative effects on the immune system and endocrine system.[61] More than half of the effect from the diet is due to overnutrition (eating too much), rather than from eating too few vegetables or other healthful foods.

Some specific foods are linked to specific cancers. A high-salt diet is linked to gastric cancer.[63] Aflatoxin B1, a frequent food contaminant, causes liver cancer.[63] Betel nut chewing can cause oral cancer.[63] National differences in dietary practices may partly explain differences in cancer incidence. For example, gastric cancer is more common in Japan due to its high-salt diet[64] while colon cancer is more common in the United States. Immigrant cancer profiles mirror those of their new country, often within one generation.[65]


Main page: Biology:Infectious causes of cancer

Worldwide, approximately 18% of cancer deaths are related to infectious diseases.[3] This proportion ranges from a high of 25% in Africa to less than 10% in the developed world.[3] Viruses[66] are the usual infectious agents that cause cancer but bacteria and parasites may also play a role. Oncoviruses (viruses that can cause human cancer) include:

Bacterial infection may also increase the risk of cancer, as seen in

Parasitic infections associated with cancer include:


Main page: Biology:Radiation-induced cancer

Radiation exposure such as ultraviolet radiation and radioactive material is a risk factor for cancer.[70][71][72] Many non-melanoma skin cancers are due to ultraviolet radiation, mostly from sunlight.[71] Sources of ionizing radiation include medical imaging and radon gas.[71]

Ionizing radiation is not a particularly strong mutagen.[73] Residential exposure to radon gas, for example, has similar cancer risks as passive smoking.[73] Radiation is a more potent source of cancer when combined with other cancer-causing agents, such as radon plus tobacco smoke.[73] Radiation can cause cancer in most parts of the body, in all animals and at any age. Children are twice as likely to develop radiation-induced leukemia as adults; radiation exposure before birth has ten times the effect.[73]

Medical use of ionizing radiation is a small but growing source of radiation-induced cancers. Ionizing radiation may be used to treat other cancers, but this may, in some cases, induce a second form of cancer.[73] It is also used in some kinds of medical imaging.[74]

Prolonged exposure to ultraviolet radiation from the sun can lead to melanoma and other skin malignancies.[75] Clear evidence establishes ultraviolet radiation, especially the non-ionizing medium wave UVB, as the cause of most non-melanoma skin cancers, which are the most common forms of cancer in the world.[75]

Non-ionizing radio frequency radiation from mobile phones, electric power transmission and other similar sources has been described as a possible carcinogen by the World Health Organization's International Agency for Research on Cancer.[76] Evidence, however, has not supported a concern.[77] [70] This includes that studies have not found a consistent link between mobile phone radiation and cancer risk.[78]


Main page: Medicine:Cancer syndrome

The vast majority of cancers are non-hereditary (sporadic). Hereditary cancers are primarily caused by an inherited genetic defect. Less than 0.3% of the population are carriers of a genetic mutation that has a large effect on cancer risk and these cause less than 3–10% of cancer.[79] Some of these syndromes include: certain inherited mutations in the genes BRCA1 and BRCA2 with a more than 75% risk of breast cancer and ovarian cancer,[79] and hereditary nonpolyposis colorectal cancer (HNPCC or Lynch syndrome), which is present in about 3% of people with colorectal cancer,[80] among others.

Statistically for cancers causing most mortality, the relative risk of developing colorectal cancer when a first-degree relative (parent, sibling or child) has been diagnosed with it is about 2.[81] The corresponding relative risk is 1.5 for lung cancer,[82] and 1.9 for prostate cancer.[83] For breast cancer, the relative risk is 1.8 with a first-degree relative having developed it at 50 years of age or older, and 3.3 when the relative developed it when being younger than 50 years of age.[84]

Taller people have an increased risk of cancer because they have more cells than shorter people. Since height is genetically determined to a large extent, taller people have a heritable increase of cancer risk.[85]

Physical agents

Some substances cause cancer primarily through their physical, rather than chemical, effects.[86] A prominent example of this is prolonged exposure to asbestos, naturally occurring mineral fibers that are a major cause of mesothelioma (cancer of the serous membrane) usually the serous membrane surrounding the lungs.[86] Other substances in this category, including both naturally occurring and synthetic asbestos-like fibers, such as wollastonite, attapulgite, glass wool and rock wool, are believed to have similar effects.[86] Non-fibrous particulate materials that cause cancer include powdered metallic cobalt and nickel and crystalline silica (quartz, cristobalite and tridymite).[86] Usually, physical carcinogens must get inside the body (such as through inhalation) and require years of exposure to produce cancer.[86]

Physical trauma resulting in cancer is relatively rare.[87] Claims that breaking bones resulted in bone cancer, for example, have not been proven.[87] Similarly, physical trauma is not accepted as a cause for cervical cancer, breast cancer or brain cancer.[87] One accepted source is frequent, long-term application of hot objects to the body. It is possible that repeated burns on the same part of the body, such as those produced by kanger and kairo heaters (charcoal hand warmers), may produce skin cancer, especially if carcinogenic chemicals are also present.[87] Frequent consumption of scalding hot tea may produce esophageal cancer.[87] Generally, it is believed that cancer arises, or a pre-existing cancer is encouraged, during the process of healing, rather than directly by the trauma.[87] However, repeated injuries to the same tissues might promote excessive cell proliferation, which could then increase the odds of a cancerous mutation.

Chronic inflammation has been hypothesized to directly cause mutation.[87][88] Inflammation can contribute to proliferation, survival, angiogenesis and migration of cancer cells by influencing the tumor microenvironment.[89][90] Oncogenes build up an inflammatory pro-tumorigenic microenvironment.[91]


Some hormones play a role in the development of cancer by promoting cell proliferation.[92] Insulin-like growth factors and their binding proteins play a key role in cancer cell proliferation, differentiation and apoptosis, suggesting possible involvement in carcinogenesis.[93]

Hormones are important agents in sex-related cancers, such as cancer of the breast, endometrium, prostate, ovary and testis and also of thyroid cancer and bone cancer.[92] For example, the daughters of women who have breast cancer have significantly higher levels of estrogen and progesterone than the daughters of women without breast cancer. These higher hormone levels may explain their higher risk of breast cancer, even in the absence of a breast-cancer gene.[92] Similarly, men of African ancestry have significantly higher levels of testosterone than men of European ancestry and have a correspondingly higher level of prostate cancer.[92] Men of Asian ancestry, with the lowest levels of testosterone-activating androstanediol glucuronide, have the lowest levels of prostate cancer.[92]

Other factors are relevant: obese people have higher levels of some hormones associated with cancer and a higher rate of those cancers.[92] Women who take hormone replacement therapy have a higher risk of developing cancers associated with those hormones.[92] On the other hand, people who exercise far more than average have lower levels of these hormones and lower risk of cancer.[92] Osteosarcoma may be promoted by growth hormones.[92] Some treatments and prevention approaches leverage this cause by artificially reducing hormone levels and thus discouraging hormone-sensitive cancers.[92]

Autoimmune diseases

There is an association between celiac disease and an increased risk of all cancers. People with untreated celiac disease have a higher risk, but this risk decreases with time after diagnosis and strict treatment, probably due to the adoption of a gluten-free diet, which seems to have a protective role against development of malignancy in people with celiac disease. However, the delay in diagnosis and initiation of a gluten-free diet seems to increase the risk of malignancies.[94] Rates of gastrointestinal cancers are increased in people with Crohn's disease and ulcerative colitis, due to chronic inflammation. Also, immunomodulators and biologic agents used to treat these diseases may promote developing extra-intestinal malignancies.[95]


Main page: Biology:Carcinogenesis


Main page: Biology:Oncogenomics
Cancers are caused by a series of mutations. Each mutation alters the behavior of the cell somewhat.

Cancer is fundamentally a disease of tissue growth regulation. For a normal cell to transform into a cancer cell, the genes that regulate cell growth and differentiation must be altered.[96]

The affected genes are divided into two broad categories. Oncogenes are genes that promote cell growth and reproduction. Tumor suppressor genes are genes that inhibit cell division and survival. Malignant transformation can occur through the formation of novel oncogenes, the inappropriate over-expression of normal oncogenes, or by the under-expression or disabling of tumor suppressor genes. Typically, changes in multiple genes are required to transform a normal cell into a cancer cell.[97]

Genetic changes can occur at different levels and by different mechanisms. The gain or loss of an entire chromosome can occur through errors in mitosis. More common are mutations, which are changes in the nucleotide sequence of genomic DNA.

Large-scale mutations involve the deletion or gain of a portion of a chromosome. Genomic amplification occurs when a cell gains copies (often 20 or more) of a small chromosomal locus, usually containing one or more oncogenes and adjacent genetic material. Translocation occurs when two separate chromosomal regions become abnormally fused, often at a characteristic location. A well-known example of this is the Philadelphia chromosome, or translocation of chromosomes 9 and 22, which occurs in chronic myelogenous leukemia and results in production of the BCR-abl fusion protein, an oncogenic tyrosine kinase.

Small-scale mutations include point mutations, deletions, and insertions, which may occur in the promoter region of a gene and affect its expression, or may occur in the gene's coding sequence and alter the function or stability of its protein product. Disruption of a single gene may also result from integration of genomic material from a DNA virus or retrovirus, leading to the expression of viral oncogenes in the affected cell and its descendants.

Replication of the data contained within the DNA of living cells will probabilistically result in some errors (mutations). Complex error correction and prevention are built into the process and safeguard the cell against cancer. If a significant error occurs, the damaged cell can self-destruct through programmed cell death, termed apoptosis. If the error control processes fail, then the mutations will survive and be passed along to daughter cells.

Some environments make errors more likely to arise and propagate. Such environments can include the presence of disruptive substances called carcinogens, repeated physical injury, heat, ionising radiation, or hypoxia.[98]

The errors that cause cancer are self-amplifying and compounding, for example:

  • A mutation in the error-correcting machinery of a cell might cause that cell and its children to accumulate errors more rapidly.
  • A further mutation in an oncogene might cause the cell to reproduce more rapidly and more frequently than its normal counterparts.
  • A further mutation may cause loss of a tumor suppressor gene, disrupting the apoptosis signaling pathway and immortalizing the cell.
  • A further mutation in the signaling machinery of the cell might send error-causing signals to nearby cells.

The transformation of a normal cell into cancer is akin to a chain reaction caused by initial errors, which compound into more severe errors, each progressively allowing the cell to escape more controls that limit normal tissue growth. This rebellion-like scenario is an undesirable survival of the fittest, where the driving forces of evolution work against the body's design and enforcement of order. Once cancer has begun to develop, this ongoing process, termed clonal evolution, drives progression towards more invasive stages.[99] Clonal evolution leads to intra-tumour heterogeneity (cancer cells with heterogeneous mutations) that complicates designing effective treatment strategies and requires an evolutionary approach to designing treatment.

Characteristic abilities developed by cancers are divided into categories, specifically evasion of apoptosis, self-sufficiency in growth signals, insensitivity to anti-growth signals, sustained angiogenesis, limitless replicative potential, metastasis, reprogramming of energy metabolism and evasion of immune destruction.[30][31]


Main page: Biology:Cancer epigenetics
The central role of DNA damage and epigenetic defects in DNA repair genes in carcinogenesis

The classical view of cancer is a set of diseases driven by progressive genetic abnormalities that include mutations in tumor-suppressor genes and oncogenes, and in chromosomal abnormalities. A role for epigenetic alterations was identified in the early 21st century.[100]

Epigenetic alterations are functionally relevant modifications to the genome that do not change the nucleotide sequence. Examples of such modifications are changes in DNA methylation (hypermethylation and hypomethylation), histone modification[101] and changes in chromosomal architecture (caused by inappropriate expression of proteins such as HMGA2 or HMGA1).[102] Each of these alterations regulates gene expression without altering the underlying DNA sequence. These changes may remain through cell divisions, endure for multiple generations, and can be considered as equivalent to mutations.

Epigenetic alterations occur frequently in cancers. As an example, one study listed protein coding genes that were frequently altered in their methylation in association with colon cancer. These included 147 hypermethylated and 27 hypomethylated genes. Of the hypermethylated genes, 10 were hypermethylated in 100% of colon cancers and many others were hypermethylated in more than 50% of colon cancers.[103]

While epigenetic alterations are found in cancers, the epigenetic alterations in DNA repair genes, causing reduced expression of DNA repair proteins, may be of particular importance. Such alterations may occur early in progression to cancer and are a possible cause of the genetic instability characteristic of cancers.[104][105][106]

Reduced expression of DNA repair genes disrupts DNA repair. This is shown in the figure at the 4th level from the top. (In the figure, red wording indicates the central role of DNA damage and defects in DNA repair in progression to cancer.) When DNA repair is deficient DNA damage remains in cells at a higher than usual level (5th level) and causes increased frequencies of mutation and/or epimutation (6th level). Mutation rates increase substantially in cells defective in DNA mismatch repair[107][108] or in homologous recombinational repair (HRR).[109] Chromosomal rearrangements and aneuploidy also increase in HRR defective cells.[110]

Higher levels of DNA damage cause increased mutation (right side of figure) and increased epimutation. During repair of DNA double strand breaks, or repair of other DNA damage, incompletely cleared repair sites can cause epigenetic gene silencing.[111][112]

Deficient expression of DNA repair proteins due to an inherited mutation can increase cancer risks. Individuals with an inherited impairment in any of 34 DNA repair genes (see article DNA repair-deficiency disorder) have increased cancer risk, with some defects ensuring a 100% lifetime chance of cancer (e.g. p53 mutations).[113] Germ line DNA repair mutations are noted on the figure's left side. However, such germline mutations (which cause highly penetrant cancer syndromes) are the cause of only about 1 percent of cancers.[114]

In sporadic cancers, deficiencies in DNA repair are occasionally caused by a mutation in a DNA repair gene but are much more frequently caused by epigenetic alterations that reduce or silence expression of DNA repair genes. This is indicated in the figure at the 3rd level. Many studies of heavy metal-induced carcinogenesis show that such heavy metals cause a reduction in expression of DNA repair enzymes, some through epigenetic mechanisms. DNA repair inhibition is proposed to be a predominant mechanism in heavy metal-induced carcinogenicity. In addition, frequent epigenetic alterations of the DNA sequences code for small RNAs called microRNAs (or miRNAs). miRNAs do not code for proteins, but can "target" protein-coding genes and reduce their expression.

Cancers usually arise from an assemblage of mutations and epimutations that confer a selective advantage leading to clonal expansion (see Field defects in progression to cancer). Mutations, however, may not be as frequent in cancers as epigenetic alterations. An average cancer of the breast or colon can have about 60 to 70 protein-altering mutations, of which about three or four may be "driver" mutations and the remaining ones may be "passenger" mutations.[115]


Main page: Medicine:Metastasis

Metastasis is the spread of cancer to other locations in the body. The dispersed tumors are called metastatic tumors, while the original is called the primary tumor. Almost all cancers can metastasize.[39] Most cancer deaths are due to cancer that has metastasized.[40]

Metastasis is common in the late stages of cancer and it can occur via the blood or the lymphatic system or both. The typical steps in metastasis are local invasion, intravasation into the blood or lymph, circulation through the body, extravasation into the new tissue, proliferation and angiogenesis. Different types of cancers tend to metastasize to particular organs, but overall the most common places for metastases to occur are the lungs, liver, brain and the bones.[39]


Main page: Biology:Tumor metabolome

Normal cells typically generate only about 30% of energy from glycolysis,[116] whereas most cancers rely on glycolysis for energy production (Warburg effect).[117][118] But a minority of cancer types rely on oxidative phosphorylation as the primary energy source, including lymphoma, leukemia, and endometrial cancer.[119] Even in these cases, however, the use of glycolysis as an energy source rarely exceeds 60%.[116] A few cancers use glutamine as the major energy source, partly because it provides nitrogen required for nucleotide (DNA, RNA) synthesis.[120] Cancer stem cells often use oxidative phosphorylation or glutamine as a primary energy source.[121]


Chest X-ray showing lung cancer in the left lung

Most cancers are initially recognized either because of the appearance of signs or symptoms or through screening.[122] Neither of these leads to a definitive diagnosis, which requires the examination of a tissue sample by a pathologist.[123] People with suspected cancer are investigated with medical tests. These commonly include blood tests, X-rays, (contrast) CT scans and endoscopy.

The tissue diagnosis from the biopsy indicates the type of cell that is proliferating, its histological grade, genetic abnormalities and other features. Together, this information is useful to evaluate the prognosis and to choose the best treatment.

Cytogenetics and immunohistochemistry are other types of tissue tests. These tests provide information about molecular changes (such as mutations, fusion genes and numerical chromosome changes) and may thus also indicate the prognosis and best treatment.

Cancer diagnosis can cause psychological distress and psychosocial interventions, such as talking therapy, may help people with this.[124] Some people choose to disclose the diagnosis widely; others prefer to keep the information private, especially shortly after the diagnosis, or to disclose it only partially or to selected people.[125]


A large proportion of cancers are adenocarcinomas, with typical histopathology features shown, although they vary substantially from case to case.

Cancers are classified by the type of cell that the tumor cells resemble and is therefore presumed to be the origin of the tumor. These types include:

  • Carcinoma: Cancers derived from epithelial cells. This group includes many of the most common cancers and include nearly all those in the breast, prostate, lung, pancreas and colon. Most of these are of the adenocarcinoma type, which means that the cancer has gland-like differentiation.
  • Sarcoma: Cancers arising from connective tissue (i.e. bone, cartilage, fat, nerve), each of which develops from cells originating in mesenchymal cells outside the bone marrow.
  • Lymphoma and leukemia: These two classes arise from hematopoietic (blood-forming) cells that leave the marrow and tend to mature in the lymph nodes and blood, respectively.[126]
  • Germ cell tumor: Cancers derived from pluripotent cells, most often presenting in the testicle or the ovary (seminoma and dysgerminoma, respectively).
  • Blastoma: Cancers derived from immature "precursor" cells or embryonic tissue.

Cancers are usually named using -carcinoma, -sarcoma or -blastoma as a suffix, with the Latin or Greek word for the organ or tissue of origin as the root. For example, cancers of the liver parenchyma arising from malignant epithelial cells is called hepatocarcinoma, while a malignancy arising from primitive liver precursor cells is called a hepatoblastoma and a cancer arising from fat cells is called a liposarcoma. For some common cancers, the English organ name is used. For example, the most common type of breast cancer is called ductal carcinoma of the breast. Here, the adjective ductal refers to the appearance of cancer under the microscope, which suggests that it has originated in the milk ducts.

Benign tumors (which are not cancers) are named using -oma as a suffix with the organ name as the root. For example, a benign tumor of smooth muscle cells is called a leiomyoma (the common name of this frequently occurring benign tumor in the uterus is fibroid). Confusingly, some types of cancer use the -noma suffix, examples including melanoma and seminoma.

Some types of cancer are named for the size and shape of the cells under a microscope, such as giant cell carcinoma, spindle cell carcinoma and small-cell carcinoma.


Main page: Medicine:Cancer prevention
Global deaths from cancers attributable to risk factors in 2019 by sex and Socio-demographic Index.[128]
Cancer DALYs attributable to 11 Level 2 risk factors globally in 2019.[128]

Cancer prevention is defined as active measures to decrease cancer risk.[129] The vast majority of cancer cases are due to environmental risk factors. Many of these environmental factors are controllable lifestyle choices. Thus, cancer is generally preventable.[130] Between 70% and 90% of common cancers are due to environmental factors and therefore potentially preventable.[131]

Greater than 30% of cancer deaths could be prevented by avoiding risk factors including: tobacco, excess weight/obesity, poor diet, physical inactivity, alcohol, sexually transmitted infections and air pollution.[132] Further, poverty could be considered as an indirect risk factor in human cancers.[133] Not all environmental causes are controllable, such as naturally occurring background radiation and cancers caused through hereditary genetic disorders and thus are not preventable via personal behavior.

In 2019, ~44% of all cancer deaths – or ~4.5 M deaths or ~105 million lost disability-adjusted life years – were due to known clearly preventable risk factors, led by smoking, alcohol use and high BMI, according to a GBD systematic analysis.[128]


Main page: Medicine:Diet and cancer

While many dietary recommendations have been proposed to reduce cancer risks, the evidence to support them is not definitive.[14][134] The primary dietary factors that increase risk are obesity and alcohol consumption. Diets low in fruits and vegetables and high in red meat have been implicated but reviews and meta-analyses do not come to a consistent conclusion.[135][136] A 2014 meta-analysis found no relationship between fruits and vegetables and cancer.[137] Coffee is associated with a reduced risk of liver cancer.[138] Studies have linked excessive consumption of red or processed meat to an increased risk of breast cancer, colon cancer and pancreatic cancer, a phenomenon that could be due to the presence of carcinogens in meats cooked at high temperatures.[139][140] In 2015 the IARC reported that eating processed meat (e.g., bacon, ham, hot dogs, sausages) and, to a lesser degree, red meat was linked to some cancers.[141][142]

Dietary recommendations for cancer prevention typically include an emphasis on vegetables, fruit, whole grains and fish and an avoidance of processed and red meat (beef, pork, lamb), animal fats, pickled foods and refined carbohydrates.[14][134]


Medications can be used to prevent cancer in a few circumstances.[143] In the general population, NSAIDs reduce the risk of colorectal cancer; however, due to cardiovascular and gastrointestinal side effects, they cause overall harm when used for prevention.[144] Aspirin has been found to reduce the risk of death from cancer by about 7%.[145] COX-2 inhibitors may decrease the rate of polyp formation in people with familial adenomatous polyposis; however, it is associated with the same adverse effects as NSAIDs.[146] Daily use of tamoxifen or raloxifene reduce the risk of breast cancer in high-risk women.[147] The benefit versus harm for 5-alpha-reductase inhibitor such as finasteride is not clear.[148]

Vitamin supplementation does not appear to be effective at preventing cancer.[149] While low blood levels of vitamin D are correlated with increased cancer risk,[150][151][152] whether this relationship is causal and vitamin D supplementation is protective is not determined.[153][154] One 2014 review found that supplements had no significant effect on cancer risk.[154] Another 2014 review concluded that vitamin D3 may decrease the risk of death from cancer (one fewer death in 150 people treated over 5 years), but concerns with the quality of the data were noted.[155]

Beta-Carotene supplementation increases lung cancer rates in those who are high risk.[156] Folic acid supplementation is not effective in preventing colon cancer and may increase colon polyps.[157] Selenium supplementation has not been shown to reduce the risk of cancer.[158]


Vaccines have been developed that prevent infection by some carcinogenic viruses.[159] Human papillomavirus vaccine (Gardasil and Cervarix) decrease the risk of developing cervical cancer.[159] The hepatitis B vaccine prevents infection with hepatitis B virus and thus decreases the risk of liver cancer.[159] The administration of human papillomavirus and hepatitis B vaccinations is recommended where resources allow.[160]


Unlike diagnostic efforts prompted by symptoms and medical signs, cancer screening involves efforts to detect cancer after it has formed, but before any noticeable symptoms appear.[161] This may involve physical examination, blood or urine tests or medical imaging.[161]

Cancer screening is not available for many types of cancers. Even when tests are available, they may not be recommended for everyone. Universal screening or mass screening involves screening everyone.[162] Selective screening identifies people who are at higher risk, such as people with a family history.[162] Several factors are considered to determine whether the benefits of screening outweigh the risks and the costs of screening.[161] These factors include:

  • Possible harms from the screening test: for example, X-ray images involve exposure to potentially harmful ionizing radiation
  • The likelihood of the test correctly identifying cancer
  • The likelihood that cancer is present: Screening is not normally useful for rare cancers.
  • Possible harms from follow-up procedures
  • Whether suitable treatment is available
  • Whether early detection improves treatment outcomes
  • Whether cancer will ever need treatment
  • Whether the test is acceptable to the people: If a screening test is too burdensome (for example, extremely painful), then people will refuse to participate.[162]
  • Cost


U.S. Preventive Services Task Force

The U.S. Preventive Services Task Force (USPSTF) issues recommendations for various cancers:


Screens for gastric cancer using photofluorography due to the high incidence there.[25]

Genetic testing

Gene Cancer types
BRCA1, BRCA2 Breast, ovarian, pancreatic
HNPCC, MLH1, MSH2, MSH6, PMS1, PMS2 Colon, uterine, small bowel, stomach, urinary tract

Genetic testing for individuals at high-risk of certain cancers is recommended by unofficial groups.[160][176] Carriers of these mutations may then undergo enhanced surveillance, chemoprevention, or preventative surgery to reduce their subsequent risk.[176]


Main pages: Medicine:Treatment of cancer and Medicine:Oncology

Many treatment options for cancer exist. The primary ones include surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy and palliative care. Which treatments are used depends on the type, location and grade of the cancer as well as the patient's health and preferences. The treatment intent may or may not be curative.


Chemotherapy is the treatment of cancer with one or more cytotoxic anti-neoplastic drugs (chemotherapeutic agents) as part of a standardized regimen. The term encompasses a variety of drugs, which are divided into broad categories such as alkylating agents and antimetabolites.[177] Traditional chemotherapeutic agents act by killing cells that divide rapidly, a critical property of most cancer cells.

It was found that providing combined cytotoxic drugs is better than a single drug, a process called the combination therapy, which has an advantage in the statistics of survival and response to the tumor and in the progress of the disease.[178] A Cochrane review concluded that combined therapy was more effective to treat metastasized breast cancer. However, generally it is not certain whether combination chemotherapy leads to better health outcomes, when both survival and toxicity are considered.[179]

Targeted therapy is a form of chemotherapy that targets specific molecular differences between cancer and normal cells. The first targeted therapies blocked the estrogen receptor molecule, inhibiting the growth of breast cancer. Another common example is the class of Bcr-Abl inhibitors, which are used to treat chronic myelogenous leukemia (CML).[4] Currently, targeted therapies exist for many of the most common cancer types, including bladder cancer, breast cancer, colorectal cancer, kidney cancer, leukemia, liver cancer, lung cancer, lymphoma, pancreatic cancer, prostate cancer, skin cancer, and thyroid cancer as well as other cancer types.[180]

The efficacy of chemotherapy depends on the type of cancer and the stage. In combination with surgery, chemotherapy has proven useful in cancer types including breast cancer, colorectal cancer, pancreatic cancer, osteogenic sarcoma, testicular cancer, ovarian cancer and certain lung cancers.[181] Chemotherapy is curative for some cancers, such as some leukemias,[182][183] ineffective in some brain tumors,[184] and needless in others, such as most non-melanoma skin cancers.[185] The effectiveness of chemotherapy is often limited by its toxicity to other tissues in the body. Even when chemotherapy does not provide a permanent cure, it may be useful to reduce symptoms such as pain or to reduce the size of an inoperable tumor in the hope that surgery will become possible in the future.


Radiation therapy involves the use of ionizing radiation in an attempt to either cure or improve symptoms. It works by damaging the DNA of cancerous tissue, causing mitotic catastrophe resulting in the death of the cancer cells.[186] To spare normal tissues (such as skin or organs, which radiation must pass through to treat the tumor), shaped radiation beams are aimed from multiple exposure angles to intersect at the tumor, providing a much larger dose there than in the surrounding, healthy tissue. As with chemotherapy, cancers vary in their response to radiation therapy.[187][188][189]

Radiation therapy is used in about half of cases. The radiation can be either from internal sources (brachytherapy) or external sources. The radiation is most commonly low energy X-rays for treating skin cancers, while higher energy X-rays are used for cancers within the body.[190] Radiation is typically used in addition to surgery and or chemotherapy. For certain types of cancer, such as early head and neck cancer, it may be used alone.[191] Radiation therapy after surgery for brain metastases has been shown to not improve overall survival in patients compared to surgery alone.[192] For painful bone metastasis, radiation therapy has been found to be effective in about 70% of patients.[191]


Surgery is the primary method of treatment for most isolated, solid cancers and may play a role in palliation and prolongation of survival. It is typically an important part of definitive diagnosis and staging of tumors, as biopsies are usually required. In localized cancer, surgery typically attempts to remove the entire mass along with, in certain cases, the lymph nodes in the area. For some types of cancer this is sufficient to eliminate the cancer.[181]

Palliative care

Palliative care is treatment that attempts to help the patient feel better and may be combined with an attempt to treat the cancer. Palliative care includes action to reduce physical, emotional, spiritual and psycho-social distress. Unlike treatment that is aimed at directly killing cancer cells, the primary goal of palliative care is to improve quality of life.

People at all stages of cancer treatment typically receive some kind of palliative care. In some cases, medical specialty professional organizations recommend that patients and physicians respond to cancer only with palliative care.[193] This applies to patients who:[194]

  1. display low performance status, implying limited ability to care for themselves[193]
  2. received no benefit from prior evidence-based treatments[193]
  3. are not eligible to participate in any appropriate clinical trial[193]
  4. no strong evidence implies that treatment would be effective[193]

Palliative care may be confused with hospice and therefore only indicated when people approach end of life. Like hospice care, palliative care attempts to help the patient cope with their immediate needs and to increase comfort. Unlike hospice care, palliative care does not require people to stop treatment aimed at the cancer.

Multiple national medical guidelines recommend early palliative care for patients whose cancer has produced distressing symptoms or who need help coping with their illness. In patients first diagnosed with metastatic disease, palliative care may be immediately indicated. Palliative care is indicated for patients with a prognosis of less than 12 months of life even given aggressive treatment.[195][196][197]


Main page: Chemistry:Cancer immunotherapy

A variety of therapies using immunotherapy, stimulating or helping the immune system to fight cancer, have come into use since 1997. Approaches include antibodies, checkpoint therapy, and adoptive cell transfer.[198]

Laser therapy

Main page: Physics:Lasers in cancer treatment

Laser therapy uses high-intensity light to treat cancer by shrinking or destroying tumors or precancerous growths. Lasers are most commonly used to treat superficial cancers that are on the surface of the body or the lining of internal organs. It is used to treat basal cell skin cancer and the very early stages of others like cervical, penile, vaginal, vulvar, and non-small cell lung cancer. It is often combined with other treatments, such as surgery, chemotherapy, or radiation therapy. Laser-induced interstitial thermotherapy (LITT), or interstitial laser photocoagulation, uses lasers to treat some cancers using hyperthermia, which uses heat to shrink tumors by damaging or killing cancer cells. Laser are more precise than surgery and cause less damage, pain, bleeding, swelling, and scarring. A disadvantage is surgeons must have specialized training. It may be more expensive than other treatments.[199]

Alternative medicine

Complementary and alternative cancer treatments are a diverse group of therapies, practices and products that are not part of conventional medicine.[200] "Complementary medicine" refers to methods and substances used along with conventional medicine, while "alternative medicine" refers to compounds used instead of conventional medicine.[201] Most complementary and alternative medicines for cancer have not been studied or tested using conventional techniques such as clinical trials. Some alternative treatments have been investigated and shown to be ineffective but still continue to be marketed and promoted. Cancer researcher Andrew J. Vickers stated, "The label 'unproven' is inappropriate for such therapies; it is time to assert that many alternative cancer therapies have been 'disproven'."[202]


Three measures of global cancer mortality from 1990 to 2017[203]

Survival rates vary by cancer type and by the stage at which it is diagnosed, ranging from majority survival to complete mortality five years after diagnosis. Once a cancer has metastasized, prognosis normally becomes much worse. About half of patients receiving treatment for invasive cancer (excluding carcinoma in situ and non-melanoma skin cancers) die from that cancer or its treatment.[25] A majority of cancer deaths are due to metastases of the primary tumor.[204]

Survival is worse in the developing world,[25] partly because the types of cancer that are most common there are harder to treat than those associated with developed countries.[205]

Those who survive cancer develop a second primary cancer at about twice the rate of those never diagnosed.[206] The increased risk is believed to be due to the random chance of developing any cancer, the likelihood of surviving the first cancer, the same risk factors that produced the first cancer, unwanted side effects of treating the first cancer (particularly radiation therapy), and better compliance with screening.[206]

Predicting short- or long-term survival depends on many factors. The most important are the cancer type and the patient's age and overall health. Those who are frail with other health problems have lower survival rates than otherwise healthy people. Centenarians are unlikely to survive for five years even if treatment is successful. People who report a higher quality of life tend to survive longer.[207] People with lower quality of life may be affected by depression and other complications and/or disease progression that both impairs quality and quantity of life. Additionally, patients with worse prognoses may be depressed or report poorer quality of life because they perceive that their condition is likely to be fatal.

People with cancer have an increased risk of blood clots in their veins which can be life-threatening.[208] The use of blood thinners such as heparin decrease the risk of blood clots but have not been shown to increase survival in people with cancer.[208] People who take blood thinners also have an increased risk of bleeding.[208]

Although extremely rare, some forms of cancer, even from an advanced stage, can heal spontaneously. This phenomenon is known as the spontaneous remission.[209]


Main page: Biology:Epidemiology of cancer
<graph mode="interactive">


 // ATTENTION: This code is maintained at
 //            Please do not modify it anywhere else, as it may get copied and override your changes.
 //            Suggestions can be made at
 "version": 2,
 "width": 300,
 "height": 265,
 "signals": [
   // TODO: should be auto-calculated last available
   { "name": "initYear", "init": 2017 },
   { "name": "gapHeight", "init": 26 },
     // Hide overview if total height is too small
     "name": "showOverview",
     "init": {"expr": "true || height < (gapHeight + 100)" }
   { "name": "overviewHeight", "init": {"expr": "showOverview ? 40 : 0" } },
   { "name": "detailHeight", "init": {"expr": "height - (showOverview ? overviewHeight + gapHeight : 0)" } },
   { "name": "overviewYPos", "init": {"expr": "height - overviewHeight" } },
   { "name": "mapXC", "init": {"expr": "width/2"} },
   { "name": "mapYC", "init": {"expr": "overviewYPos/2"} },
     "name": "brush_start",
     "streams": [{
       "type": "@overview:mousedown, @overview:touchstart", 
       "expr": "clamp(eventX(), 0, width)",
       "scale": {"name": "xOverview", "invert": true}
     "name": "brush_end",
     "streams": [{
       "type": "@overview:mousedown, [@overview:mousedown, window:mouseup] > window:mousemove, @overview:mouseup, @overview:touchstart, [@overview:touchstart, window:touchend] > window:touchmove, @overview:touchend",
       "expr": "clamp(eventX(), 0, width)",
       "scale": {"name": "xOverview", "invert": true}
     "name": "fromYear", 
     "init": {"expr": "initYear"},
     "expr": "year(min(brush_start, brush_end))"
     "name": "toYear",
     "init": {"expr": "initYear"},
     "expr": "year(max(brush_start, brush_end))"
     "name": "isRange", 
     "init": {"expr": "false"},
     "expr": "fromYear !== toYear"
     "name": "tooltip",
     "init": {"expr": "{x: 0, y: 0, datum: false }"}, 
     "streams": [
       {"type": "@map:mouseout, @map:touchstart", "expr": "{x: 0, y: 0, datum: false }" },
       {"type": "@map:mouseover, @map:touchstart", "expr": "{x: eventX(), y: eventY(), datum: eventItem().datum.lookup}" }
 "data": [{
   "name": "data",
   "url": "tabular:///Cancer death",
   "format": {"type": "json", "property": "data"},
   "transform": [
     { "type": "formula", "field": "value", "expr": "datum.deaths" }
   "name": "totals",
   "source": "data",
   "transform": [
     	"type": "aggregate",
     	"groupby": ["year"],
       "summarize": [{"field": "value", "ops": ["sum"], "as": ["total"]}]
     { "type": "formula", "field": "date", "expr": "datetime(datum.year, 0, 1)" }
   // Select just the source data for the starting year
   "name": "firstYearData",
   "source": "data",
   "transform": [{"type": "filter", "test": "datum.year === fromYear"}]
   // Select just the source data for the ending year
   "name": "yearData",
   "source": "data",
   "transform": [{
     "type": "filter", "test": "datum.year === toYear"
     "type": "sort", "by": ["-value"]
     "type": "rank", "field": "country"
     "type": "lookup",
     "on": "firstYearData",
     "onKey": "country",
     "keys": ["country"],
     "as": ["firstYear"],
     "default": null
     "type": "formula", "field": "calc", "expr": "if(isRange, (datum.value - datum.firstYear.value)/datum.firstYear.value, datum.value)"
   "name": "mapData",
   "url": "map:///",
   "format": {"type": "json", "property": "data.features"},
   "transform": [{
     "type": "geopath",
     "projection": "equirectangular",
     "scale": 72,
     "translate": [{"expr": "mapXC"}, {"expr": "mapYC"}]
   	"type": "formula",
   	"field": "my_id",
   	"expr": " ||"
     "type": "lookup",
     "on": "yearData",
     "onKey": "country",
     "keys": ["my_id"],
     "as": ["lookup"],
     "default": 100
   "name": "dummyValue",
   "values": [{}]
 "scales": [{
   "name": "color",
   "type": "linear",
   "domain": {"data": "yearData", "field": "calc"},
   "range": ["blue", "#a50026"],
   "zero": false,
   "clamp": true
   "name": "diffColor",
   "type": "linear",
   "domain": [-1, -0.8, -0.6, -0.3, -0.1, 0, 0.1, 0.3, 0.6, 0.8, 1],
   "range": ["#313695", "#4575b4", "#74add1", "#abd9e9", "#e0f3f8", "#ffffbf", "#fee090", "#fdae61", "#f46d43", "#d73027", "#a50026"],
   "zero": false,
   "clamp": true
     "name": "xOverview",
     "type": "time",
     "range": "width",
     "domain": {"data": "totals", "field": "date"}
     "name": "yOverview",
     "type": "linear",
     "rangeMin": {"signal": "overviewHeight"},
     "nice": true,
     "zero": false,
     "domain": {"data": "totals", "field": "total"}
 "marks": [{
   "type": "group",
   "name": "detail",
   "properties": {
     "enter": {
       "height": {"signal": "detailHeight"},
       "width": {"signal": "width"}
   } },
   "marks": [{
     "name": "map",
     "type": "path",
     "from": {"data": "mapData"},
     "properties": {
       "enter": {
         "stroke": {"value": "#fff"},
         "path": {"field": "layout_path"}
       "update": {
         "fill": [
           {"test": "isRange", "field": "lookup.calc", "scale": "diffColor"},
           {"field": "lookup.calc", "scale": "color"}
   ]} } }]
   "type": "group",
   "name": "overview",
   "from": {
     "data": "dummyValue",
     // HACK: brush_end is needed to fool optimizer, because otherwise legend doesn't auto-update
     "transform": [{"type": "filter", "test": "(brush_end && 0) || showOverview"}]
   "properties": {
     "enter": {
       "x": {"value": 0},
       "y": {"signal": "overviewYPos"},
       "height": {"signal": "overviewHeight"},
       "width": {"signal": "width"},
       "fill": {"value": "transparent"}
   } },
   "axes": [
     {"type": "x", "scale": "xOverview", "ticks": 7}
   "marks": [{
     // Draw scale for a single year (I wish we could dynamically pick which scale to use for the legend)
     "type": "group",
     // HACK: brush_end is needed to fool optimizer, because otherwise legend doesn't auto-update
     "from": { "data": "dummyValue", "transform": [{"type": "filter", "test": "(brush_end && 0) || !isRange"}] },
     "properties": { "enter": { "width": {"signal": "width"} } },
       "legends": [{
         "fill": "color",
         "offset": 20,
         "properties": {"legend": {"y": {"value": 30} } }
     // Draw scale for a range (I wish we could dynamically pick which scale to use for the legend)
     "type": "group",
     "from": { "data": "dummyValue", "transform": [{"type": "filter", "test": "isRange"}] },
     "properties": { "enter": { "width": {"signal": "width"} } },
       "legends": [{
         "fill": "diffColor",
         "offset": 20,
         "properties": {
           "legend": {"y": {"value": 30} },
           "labels": {
             "text": [
               {"test": "", "value": "0"},
               {"test": "(", "template": "{{|number:'.0%'}}"},
               {"value": ""}
   ]} } }]},{
     "name": "yearLabel",
     "type": "text",
     "from": {
       "data": "dummyValue",
       "transform": [
         {"type": "formula", "field": "text", "expr": "if(isRange,fromYear + '-' + toYear, fromYear)"},
         {"type": "formula", "field": "fontSize", "expr": "if(isRange,22,32)"}
     "properties": {
       "enter": {
         "x": {"signal": "width", "offset": 72},
         "y": {"value": 20},
         "fontWeight": {"value": "bold"},
         "align": {"value": "center"},
         "baseline": {"value": "middle"},
         "fill": {"value": "#08306b"}
       "update": {
         "fontSize": {"field": "fontSize"},
          "text": {"field": "text"}
   } } },{
     "type": "line",
     "from": { "data": "totals" },
     "properties": {
       "update": {
         "x": {"scale": "xOverview", "field": "date"},
         "y": {"scale": "yOverview", "field": "total"},
         "stroke": {"value": "#08306b"},
         "strokeWidth": {"value": 2}
   } } },{
     "type": "rect",
     "from": {
       "data": "dummyValue",
       "transform": [
         {"type": "formula", "field": "fromDate", "expr": "datetime(fromYear, -6, 1)"},
         {"type": "formula", "field": "toDate", "expr": "datetime(toYear, 6, 1)"}
     "properties": {
       "enter": {
         "y": {"value": 0},
         "height": {"signal": "overviewHeight"},
         "fill": {"value": "#333"},
         "fillOpacity": {"value": 0.2},
         "stroke": {"value": "#f00"},
         "strokeDash": {"value": [4]}
       "update": {
         "x": {"scale": "xOverview", "field": "fromDate"},
         "x2": {"scale": "xOverview", "field": "toDate"}
 } } }]},
   "name": "tooltip",
     "type": "group",
     "from": {
       "data": "dummyValue",
       "transform": [
         {"type": "filter", "test": "tooltip.datum && tooltip.datum.calc"},
         {"type": "formula", "field": "offsetX", "expr": "5"},
         {"type": "formula", "field": "offsetY", "expr": "30"},
         {"type": "formula", "field": "tipWidth", "expr": "200"},
         {"type": "formula", "field": "tipHeight", "expr": "51"},
         {"type": "formula", "field": "alignLeft", "expr": "tooltip.x > width - datum.offsetX - datum.tipWidth"},
         {"type": "formula", "field": "alignTop", "expr": "tooltip.y > height - datum.offsetY - datum.tipHeight"},
         {"type": "formula", "field": "x", "expr": "max(0, tooltip.x + (datum.alignLeft ? -datum.offsetX-datum.tipWidth : datum.offsetX ))"},
         {"type": "formula", "field": "y", "expr": "tooltip.y + (datum.alignTop ? -1 : 1) * datum.offsetY"},
         {"type": "formula", "field": "lookupCountry", "expr": ""},

{ "type": "lookup", "on": "mapData", "onKey": "my_id", "keys": ["lookupCountry"], "as": ["mapDataVal"], "default": null },

         {"type": "formula", "field": "name", "expr": "datum.mapDataVal ? : '?xyz?'"},

{ "type": "lookup", "on": "yearData", "onKey": "country", "keys": ["lookupCountry"], "as": ["yearDataVal"], "default": null },

         {"type": "formula", "field": "rank", "expr": "datum.yearDataVal ? datum.yearDataVal.rank : 1000"}
     "properties": {
       "update": {
         "x": {"field": "x" }, "y": {"field": "y" },
         "width": {"field": "tipWidth" },
         "height": {"field": "tipHeight" },
         "fill": {"value": "#fff"},
         "fillOpacity": {"value": 0.85},
         "stroke": {"value": "#aaa"},
         "strokeWidth": {"value": 0.5}
     } },
     "marks": [
         "type": "text",
         "properties": {
           "update": {
             "x": {"value": 6}, "y": {"value": 14},
             "text": {"template": "{{}}"},
             "fill": {"value": "black"},
             "fontWeight": {"value": "bold"}
       } } },
         "type": "text",
         "properties": {
           "update": {
             "x": {"value": 6}, "y": {"value": 29},
             "text": [
               {"test": "isRange", "template": "Growth:\t{{tooltip.datum.calc|number:'.1%'}}"},
               {"template": "Deaths per 10,000:\t{{tooltip.datum.calc|number:',.1f'}}"}
             "fill": {"value": "black"}
       } } },
         "type": "text",
         "properties": {
           "update": {
             "x": {"value": 6}, "y": {"value": 44},
             "text": [
               {"test": "isRange", "template": ""},
               {"template": "Global position:\t#{{parent.rank|number:'.0f'}}"}
             "fill": {"value": "black"}
       } } },

} </graph>

Lua error in Module:TNT at line 159: Missing JsonConfig extension; Cannot load
Age-standardized death rate from cancer per 10,000 people.[210]

Estimates are that in 2018, 18.1 million new cases of cancer and 9.6 million deaths occur globally.[211] About 20% of males and 17% of females will get cancer at some point in time while 13% of males and 9% of females will die from it.[211]

In 2008, approximately 12.7 million cancers were diagnosed (excluding non-melanoma skin cancers and other non-invasive cancers)[25] and in 2010 nearly 7.98 million people died.[212] Cancers account for approximately 16% of deaths. The most common (As of 2018) are lung cancer (1.76 million deaths), colorectal cancer (860,000) stomach cancer (780,000), liver cancer (780,000), and breast cancer (620,000).[2] This makes invasive cancer the leading cause of death in the developed world and the second leading in the developing world.[25] Over half of cases occur in the developing world.[25]

Deaths from cancer were 5.8 million in 1990.[212] Deaths have been increasing primarily due to longer lifespans and lifestyle changes in the developing world.[25] The most significant risk factor for developing cancer is age.[213] Although it is possible for cancer to strike at any age, most patients with invasive cancer are over 65.[213] According to cancer researcher Robert A. Weinberg, "If we lived long enough, sooner or later we all would get cancer."[214] Some of the association between aging and cancer is attributed to immunosenescence,[215] errors accumulated in DNA over a lifetime[216] and age-related changes in the endocrine system.[217] Aging's effect on cancer is complicated by factors such as DNA damage and inflammation promoting it and factors such as vascular aging and endocrine changes inhibiting it.[218]

Some slow-growing cancers are particularly common, but often are not fatal. Autopsy studies in Europe and Asia showed that up to 36% of people have undiagnosed and apparently harmless thyroid cancer at the time of their deaths and that 80% of men develop prostate cancer by age 80.[219][220] As these cancers do not cause the patient's death, identifying them would have represented overdiagnosis rather than useful medical care.

The three most common childhood cancers are leukemia (34%), brain tumors (23%) and lymphomas (12%).[221] In the United States cancer affects about 1 in 285 children.[222] Rates of childhood cancer increased by 0.6% per year between 1975 and 2002 in the United States[223] and by 1.1% per year between 1978 and 1997 in Europe.[221] Death from childhood cancer decreased by half between 1975 and 2010 in the United States.[222]


Main page: Medicine:History of cancer
Engraving with two views of a Dutch woman who had a tumor removed from her neck in 1689

Cancer has existed for all of human history.[224] The earliest written record regarding cancer is from circa 1600 BC in the Egyptian Edwin Smith Papyrus and describes breast cancer.[224] Hippocrates (c. 460 BCc. 370 BC) described several kinds of cancer, referring to them with the Greek word καρκίνος karkinos (crab or crayfish).[224] This name comes from the appearance of the cut surface of a solid malignant tumor, with "the veins stretched on all sides as the animal the crab has its feet, whence it derives its name".[225] Galen stated that "cancer of the breast is so called because of the fancied resemblance to a crab given by the lateral prolongations of the tumor and the adjacent distended veins".[226]:738 Celsus (c. 25 BC – 50 AD) translated karkinos into the Latin cancer, also meaning crab and recommended surgery as treatment.[224] Galen (2nd century AD) disagreed with the use of surgery and recommended purgatives instead.[224] These recommendations largely stood for 1000 years.[224]

In the 15th, 16th and 17th centuries, it became acceptable for doctors to dissect bodies to discover the cause of death.[227] The German professor Wilhelm Fabry believed that breast cancer was caused by a milk clot in a mammary duct. The Dutch professor Francois de la Boe Sylvius, a follower of Descartes, believed that all disease was the outcome of chemical processes and that acidic lymph fluid was the cause of cancer. His contemporary Nicolaes Tulp believed that cancer was a poison that slowly spreads and concluded that it was contagious.[228]

The physician John Hill described tobacco sniffing as the cause of nose cancer in 1761.[227] This was followed by the report in 1775 by British surgeon Percivall Pott that chimney sweeps' carcinoma, a cancer of the scrotum, was a common disease among chimney sweeps.[229] With the widespread use of the microscope in the 18th century, it was discovered that the 'cancer poison' spread from the primary tumor through the lymph nodes to other sites ("metastasis"). This view of the disease was first formulated by the English surgeon Campbell De Morgan between 1871 and 1874.[230]

Society and culture

Although many diseases (such as heart failure) may have a worse prognosis than most cases of cancer, cancer is the subject of widespread fear and taboos. The euphemism of "a long illness" to describe cancers leading to death is still commonly used in obituaries, rather than naming the disease explicitly, reflecting an apparent stigma.[231] Cancer is also euphemised as "the C-word";[232][233][234] Macmillan Cancer Support uses the term to try to lessen the fear around the disease.[235] In Nigeria, one local name for cancer translates into English as "the disease that cannot be cured".[236] This deep belief that cancer is necessarily a difficult and usually deadly disease is reflected in the systems chosen by society to compile cancer statistics: the most common form of cancer—non-melanoma skin cancers, accounting for about one-third of cancer cases worldwide, but very few deaths[237][238]—are excluded from cancer statistics specifically because they are easily treated and almost always cured, often in a single, short, outpatient procedure.[239]

Western conceptions of patients' rights for people with cancer include a duty to fully disclose the medical situation to the person, and the right to engage in shared decision-making in a way that respects the person's own values. In other cultures, other rights and values are preferred. For example, most African cultures value whole families rather than individualism. In parts of Africa, a diagnosis is commonly made so late that cure is not possible, and treatment, if available at all, would quickly bankrupt the family. As a result of these factors, African healthcare providers tend to let family members decide whether, when and how to disclose the diagnosis, and they tend to do so slowly and circuitously, as the person shows interest and an ability to cope with the grim news.[236] People from Asian and South American countries also tend to prefer a slower, less candid approach to disclosure than is idealized in the United States and Western Europe, and they believe that sometimes it would be preferable not to be told about a cancer diagnosis.[236] In general, disclosure of the diagnosis is more common than it was in the 20th century, but full disclosure of the prognosis is not offered to many patients around the world.[236]

In the United States and some other cultures, cancer is regarded as a disease that must be "fought" to end the "civil insurrection"; a War on Cancer was declared in the US. Military metaphors are particularly common in descriptions of cancer's human effects, and they emphasize both the state of the patient's health and the need to take immediate, decisive actions himself rather than to delay, to ignore or to rely entirely on others. The military metaphors also help rationalize radical, destructive treatments.[240][241]

In the 1970s, a relatively popular alternative cancer treatment in the US was a specialized form of talk therapy, based on the idea that cancer was caused by a bad attitude.[242] People with a "cancer personality"—depressed, repressed, self-loathing and afraid to express their emotions—were believed to have manifested cancer through subconscious desire. Some psychotherapists claimed that treatment to change the patient's outlook on life would cure the cancer.[242] Among other effects, this belief allowed society to blame the victim for having caused the cancer (by "wanting" it) or having prevented its cure (by not becoming a sufficiently happy, fearless and loving person).[243] It also increased patients' anxiety, as they incorrectly believed that natural emotions of sadness, anger or fear shorten their lives.[243] The idea was ridiculed by Susan Sontag, who published Illness as Metaphor while recovering from treatment for breast cancer in 1978.[242] Although the original idea is now generally regarded as nonsense, the idea partly persists in a reduced form with a widespread, but incorrect, belief that deliberately cultivating a habit of positive thinking will increase survival.[243] This notion is particularly strong in breast cancer culture.[243]

One idea about why people with cancer are blamed or stigmatized, called the just-world hypothesis, is that blaming cancer on the patient's actions or attitudes allows the blamers to regain a sense of control. This is based upon the blamers' belief that the world is fundamentally just and so any dangerous illness, like cancer, must be a type of punishment for bad choices, because in a just world, bad things would not happen to good people.[244]

Economic effect

The total health care expenditure on cancer in the US was estimated to be $80.2 billion in 2015.[245] Even though cancer-related health care expenditure have increased in absolute terms during recent decades, the share of health expenditure devoted to cancer treatment has remained close to 5% between the 1960s and 2004.[246][247] A similar pattern has been observed in Europe where about 6% of all health care expenditure are spent on cancer treatment.[248][249] In addition to health care expenditure and financial toxicity, cancer causes indirect costs in the form of productivity losses due to sick days, permanent incapacity and disability as well as premature death during working age. Cancer causes also costs for informal care. Indirect costs and informal care costs are typically estimated to exceed or equal the health care costs of cancer.[250][249]


In the United States, cancer is included as a protected condition by the Equal Employment Opportunity Commission (EEOC), mainly due to the potential for cancer having discriminating effects on workers.[251] Discrimination in the workplace could occur if an employer holds a false belief that a person with cancer is not capable of doing a job properly, and may ask for more sick leave than other employees. Employers may also make hiring or firing decisions based on misconceptions about cancer disabilities, if present. The EEOC provides interview guidelines for employers, as well as lists of possible solutions for assessing and accommodating employees with cancer.[251]

Divorce gender disparity

Women are six times more likely to be separated or divorced soon after a diagnosis of cancer or multiple sclerosis than men. Doctors in neuro-oncology practices noticed that divorce occurred almost exclusively when the wife was the patient.[252][253]


Main page: Medicine:Cancer research
University of Florida Cancer Hospital

Because cancer is a class of diseases,[254][255] it is unlikely that there will ever be a single "cure for cancer" any more than there will be a single treatment for all infectious diseases.[256] Angiogenesis inhibitors were once incorrectly thought to have potential as a "silver bullet" treatment applicable to many types of cancer.[257] Angiogenesis inhibitors and other cancer therapeutics are used in combination to reduce cancer morbidity and mortality.[258]

Experimental cancer treatments are studied in clinical trials to compare the proposed treatment to the best existing treatment. Treatments that succeeded in one cancer type can be tested against other types.[259] Diagnostic tests are under development to better target the right therapies to the right patients, based on their individual biology.[260]

Cancer research focuses on the following issues:

  • Agents (e.g. viruses) and events (e.g. mutations) that cause or facilitate genetic changes in cells destined to become cancer.
  • The precise nature of the genetic damage and the genes that are affected by it.
  • The consequences of those genetic changes on the biology of the cell, both in generating the defining properties of a cancer cell and in facilitating additional genetic events that lead to further progression of the cancer.

The improved understanding of molecular biology and cellular biology due to cancer research has led to new treatments for cancer since US President Richard Nixon declared the "War on Cancer" in 1971. Since then, the country has spent over $200 billion on cancer research, including resources from public and private sectors.[261] The cancer death rate (adjusting for size and age of the population) declined by five percent between 1950 and 2005.[262]

Competition for financial resources appears to have suppressed the creativity, cooperation, risk-taking and original thinking required to make fundamental discoveries, unduly favoring low-risk research into small incremental advancements over riskier, more innovative research. Other consequences of competition appear to be many studies with dramatic claims whose results cannot be replicated and perverse incentives that encourage grantee institutions to grow without making sufficient investments in their own faculty and facilities.[263][264][265][266]

Virotherapy, which uses convert viruses, is being studied.

In the wake of the COVID-19 pandemic, there has been a worry that cancer research and treatment are slowing down.[267][268]


Cancer affects approximately 1 in 1,000 pregnant women. The most common cancers found during pregnancy are the same as the most common cancers found in non-pregnant women during childbearing ages: breast cancer, cervical cancer, leukemia, lymphoma, melanoma, ovarian cancer and colorectal cancer.[269]

Diagnosing a new cancer in a pregnant woman is difficult, in part because any symptoms are commonly assumed to be a normal discomfort associated with pregnancy. As a result, cancer is typically discovered at a somewhat later stage than average. Some imaging procedures, such as MRIs (magnetic resonance imaging), CT scans, ultrasounds and mammograms with fetal shielding are considered safe during pregnancy; some others, such as PET scans, are not.[269]

Treatment is generally the same as for non-pregnant women. However, radiation and radioactive drugs are normally avoided during pregnancy, especially if the fetal dose might exceed 100 cGy. In some cases, some or all treatments are postponed until after birth if the cancer is diagnosed late in the pregnancy. Early deliveries are often used to advance the start of treatment. Surgery is generally safe, but pelvic surgeries during the first trimester may cause miscarriage. Some treatments, especially certain chemotherapy drugs given during the first trimester, increase the risk of birth defects and pregnancy loss (spontaneous abortions and stillbirths).[269]

Elective abortions are not required and, for the most common forms and stages of cancer, do not improve the mother's survival. In a few instances, such as advanced uterine cancer, the pregnancy cannot be continued and in others, the patient may end the pregnancy so that she can begin aggressive chemotherapy.[269]

Some treatments can interfere with the mother's ability to give birth vaginally or to breastfeed.[269] Cervical cancer may require birth by Caesarean section. Radiation to the breast reduces the ability of that breast to produce milk and increases the risk of mastitis. Also, when chemotherapy is given after birth, many of the drugs appear in breast milk, which could harm the baby.[269]

Other animals

Cancer mortality risk

Veterinary oncology, concentrating mainly on cats and dogs, is a growing specialty in wealthy countries and the major forms of human treatment such as surgery and radiotherapy may be offered. The most common types of cancer differ, but the cancer burden seems at least as high in pets as in humans. Animals, typically rodents, are often used in cancer research and studies of natural cancers in larger animals may benefit research into human cancer.[270]

Across wild animals, there is still limited data on cancer. Nonetheless, a study published in 2022, explored cancer risk in (non-domesticated) zoo mammals, belonging to 191 species, 110,148 individual, demonstrated that cancer is a ubiquitous disease of mammals and it can emerge anywhere along the mammalian phylogeny.[271] This research also highlighted that cancer risk is not uniformly distributed along mammals. For instance, species in the order Carnivora are particularly prone to be affected by cancer (e.g. over 25% of clouded leopards, bat-eared foxes and red wolves die of cancer), while ungulates (especially even-toed ungulates) appear to face consistently low cancer risks.

In non-humans, a few types of transmissible cancer have also been described, wherein the cancer spreads between animals by transmission of the tumor cells themselves. This phenomenon is seen in dogs with Sticker's sarcoma (also known as canine transmissible venereal tumor), and in Tasmanian devils with devil facial tumour disease (DFTD).[272]


  1. 1.0 1.1 1.2 "Cancer – Signs and symptoms". 
  2. 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 "Cancer". 12 September 2018. 
  3. 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 "Cancer is a preventable disease that requires major lifestyle changes". Pharmaceutical Research 25 (9): 2097–116. September 2008. doi:10.1007/s11095-008-9661-9. PMID 18626751. 
  4. 4.0 4.1 4.2 "Targeted Cancer Therapies". National Cancer Institute. 26 February 2018. 
  5. 5.0 5.1 "SEER Stat Fact Sheets: All Cancer Sites". National Cancer Institute. 
  6. 6.0 6.1 6.2 Kocarnik, JM; others (2022). "Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019. A Systematic Analysis for the Global Burden of Disease Study 2019". JAMA Oncology 8 (3): 420–444. doi:10.1001/jamaoncol.2021.6987. PMID 34967848. 
  7. 7.0 7.1 7.2 7.3 "Defining Cancer". National Cancer Institute. 17 September 2007. 
  8. "Obesity and Cancer Risk". National Cancer Institute. 3 January 2012. 
  9. "Long-Term Alcohol Consumption and Breast, Upper Aero-Digestive Tract and Colorectal Cancer Risk: A Systematic Review and Meta-Analysis". Alcohol and Alcoholism 51 (3): 315–30. May 2016. doi:10.1093/alcalc/agv110. PMID 26400678. 
  10. "Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis - The Lancet Global Health". 
  11. 11.0 11.1 11.2 11.3 11.4 World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 1.1. ISBN 978-92-832-0429-9. 
  12. "Heredity and Cancer". American Cancer Society. 
  13. "How is cancer diagnosed?". 29 January 2013. 
  14. 14.0 14.1 14.2 "American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity". CA: A Cancer Journal for Clinicians 62 (1): 30–67. 2012. doi:10.3322/caac.20140. PMID 22237782. 
  15. "16. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010". British Journal of Cancer 105 (Suppl 2): S77–81. December 2011. doi:10.1038/bjc.2011.489. PMID 22158327. 
  16. 16.0 16.1 World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 4.7. ISBN 978-92-832-0429-9. 
  17. "Screening for breast cancer with mammography". The Cochrane Database of Systematic Reviews 2013 (6): CD001877. June 2013. doi:10.1002/14651858.CD001877.pub5. PMID 23737396. 
  18. 18.0 18.1 World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 1.3. ISBN 978-92-832-0429-9. 
  19. GBD (8 October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015". The Lancet 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMID 27733282. 
  20. "Metabolic Drivers in Hereditary Cancer Syndromes". Annual Review of Cancer Biology 4: 77–97. 2020. doi:10.1146/annurev-cancerbio-030419-033612. 
  21. 21.0 21.1 World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 1.1. ISBN 978-92-832-0429-9. 
  22. 22.0 22.1 Siegel, Rebecca L.; Miller, Kimberly D.; Wagle, Nikita Sandeep; Jemal, Ahmedin (January 2023). "Cancer statistics, 2023" (in en). CA: A Cancer Journal for Clinicians 73 (1): 17–48. doi:10.3322/caac.21763. ISSN 0007-9235. PMID 36633525. 
  23. "Nonmelanoma skin cancer". Facial Plastic Surgery Clinics of North America 21 (1): 43–53. February 2013. doi:10.1016/j.fsc.2012.10.003. PMID 23369588. 
  24. "Epidemiology and economic burden of nonmelanoma skin cancer". Facial Plastic Surgery Clinics of North America 20 (4): 419–22. November 2012. doi:10.1016/j.fsc.2012.07.004. PMID 23084294. 
  25. 25.0 25.1 25.2 25.3 25.4 25.5 25.6 25.7 "Global cancer statistics". CA: A Cancer Journal for Clinicians 61 (2): 69–90. February 2011. doi:10.3322/caac.20107. PMID 21296855. 
  26. World Report 2014. World Health Organization. 2014. pp. Chapter 6.7. ISBN 978-92-832-0429-9. 
  27. "cancer". 
  28. "Cancer Glossary". American Cancer Society. 
  29. "What is cancer?". National Cancer Institute. 17 September 2007. 
  30. 30.0 30.1 30.2 30.3 "The hallmarks of cancer". Cell 100 (1): 57–70. January 2000. doi:10.1016/S0092-8674(00)81683-9. PMID 10647931. 
  31. 31.0 31.1 "Hallmarks of cancer: the next generation". Cell 144 (5): 646–74. March 2011. doi:10.1016/j.cell.2011.02.013. PMID 21376230. 
  32. 32.0 32.1 32.2 Holland Chp. 1
  33. "A literature review of suicide in cancer patients". Cancer Nursing 35 (4): E14–26. July–August 2012. doi:10.1097/NCC.0b013e31822fc76c. PMID 21946906. 
  34. Cancer rehabilitation principles and practice. New York: Demos Medical. 2009. p. 983. ISBN 978-1-933864-33-4. 
  35. "Definition and classification of cancer cachexia: an international consensus". The Lancet. Oncology 12 (5): 489–95. May 2011. doi:10.1016/S1470-2045(10)70218-7. PMID 21296615. 
  36. "Shortness of Breath | Cancer-related Side Effects" (in en). 
  37. Dy, Sydney M.; Gupta, Arjun; Waldfogel, Julie M.; Sharma, Ritu; Zhang, Allen; Feliciano, Josephine L.; Sedhom, Ramy; Day, Jeff et al. (2020). Interventions for Breathlessness in Patients With Advanced Cancer. AHRQ Comparative Effectiveness Reviews. Rockville (MD): Agency for Healthcare Research and Quality (US). 
  38. "Paraneoplastic endocrine syndromes". Endocrine-Related Cancer 24 (6): R173–R190. June 2017. doi:10.1530/ERC-17-0036. PMID 28341725. 
  39. 39.0 39.1 39.2 39.3 "Metastatic Cancer: Questions and Answers". National Cancer Institute. 12 May 2015. 
  40. 40.0 40.1 "What is Metastasized Cancer?". 
  41. "Why is cancer so hard to cure?". 15 July 2023. 
  42. "Share of cancer deaths attributed to tobacco". 
  43. Manton, K.G.; Akushevich, Igor; Kravchenko, Julia (28 December 2008). Cancer Mortality and Morbidity Patterns in the U.S. Population: An Interdisciplinary Approach. Springer Science & Business Media. ISBN 978-0-387-78193-8. "The term environment refers not only to air, water, and soil but also to substances and conditions at home and at the workplace, including diet, smoking, alcohol, drugs, exposure to chemicals, sunlight, ionizing radiation, electromagnetic fields, infectious agents, etc. Lifestyle, economic and behavioral factors are all aspects of our environment." 
  44. "Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States". CA: A Cancer Journal for Clinicians 68 (1): 31–54. January 2018. doi:10.3322/caac.21440. PMID 29160902. 
  45. 45.0 45.1 "Ten Surprising Facts About Stressful Life Events and Disease Risk". Annual Review of Psychology 70: 577–597. January 2019. doi:10.1146/annurev-psych-010418-102857. PMID 29949726. "the strongest conclusion derived from decades of research on stressors and cancer is that stressful events may be associated with decreased cancer survival but are probably not associated with disease incidence (Chida et al. 2008).". 
  46. "Work stress and risk of cancer: meta-analysis of 5700 incident cancer events in 116,000 European men and women". BMJ 346: f165. February 2013. doi:10.1136/bmj.f165. PMID 23393080. 
  47. 47.0 47.1 47.2 47.3 Steele, Christopher D; Pillay, Nischalan; Alexandrov, Ludmil B (July 2022). "An overview of mutational and copy number signatures in human cancer". The Journal of Pathology 257 (4): 454–465. doi:10.1002/path.5912. ISSN 0022-3417. PMID 35420163. 
  48. "Transplacental and other routes of cancer transmission between individuals". Journal of Pediatric Hematology/Oncology 25 (6): 430–4. June 2003. doi:10.1097/00043426-200306000-00002. PMID 12794519. 
  49. "European Consensus Statement on Lung Cancer: risk factors and prevention. Lung Cancer Panel". CA: A Cancer Journal for Clinicians 48 (3): 167–76; discussion 164–66. 1998. doi:10.3322/canjclin.48.3.167. PMID 9594919. 
  50. "Tobacco use and cancer causation: association by tumour type". Journal of Internal Medicine 252 (3): 206–24. September 2002. doi:10.1046/j.1365-2796.2002.01022.x. PMID 12270001. 
  51. CDC (2019-08-27). "Cancer and Tobacco Use" (in en-us). 
  52. 52.0 52.1 "Tobacco use, cancer causation and public health impact". Journal of Internal Medicine 251 (6): 455–66. June 2002. doi:10.1046/j.1365-2796.2002.00993.x. PMID 12028500. 
  53. "Tobacco smoking and cancer: a brief review of recent epidemiological evidence". Lung Cancer 45 (Suppl 2): S3–9. August 2004. doi:10.1016/j.lungcan.2004.07.998. PMID 15552776. 
  54. "How much of the decrease in cancer death rates in the United States is attributable to reductions in tobacco smoking?". Tobacco Control 15 (5): 345–47. October 2006. doi:10.1136/tc.2006.017749. PMID 16998161. 
  55. "Update in lung cancer 2007". American Journal of Respiratory and Critical Care Medicine 177 (9): 941–46. May 2008. doi:10.1164/rccm.200801-107UP. PMID 18434333. 
  56. "Alcohol attributable burden of incidence of cancer in eight European countries based on results from prospective cohort study". BMJ 342: d1584. April 2011. doi:10.1136/bmj.d1584. PMID 21474525. 
  57. "Lifestyle-related factors and environmental agents causing cancer: an overview". Biomedicine & Pharmacotherapy 61 (10): 640–58. December 2007. doi:10.1016/j.biopha.2007.10.006. PMID 18055160. 
  58. 58.0 58.1 "WHO calls for prevention of cancer through healthy workplaces" (Press release). World Health Organization. 27 April 2007. Archived from the original on 12 October 2007. Retrieved 13 October 2007.
  59. "Erin Brockovich Blasts U.S. Regulation of Toxic Chemicals". Scientific American. 28 December 2020. 
  60. "Environmental Pollutant, PFOA, Associated with Increased Risk of Kidney Cancer". National Cancer Institute. 24 September 2020. 
  61. 61.0 61.1 61.2 "American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity". CA: A Cancer Journal for Clinicians 56 (5): 254–81; quiz 313–14. 2006. doi:10.3322/canjclin.56.5.254. PMID 17005596. 
  62. "Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults". Lancet 384 (9945): 755–65. August 2014. doi:10.1016/S0140-6736(14)60892-8. PMID 25129328. 
  63. 63.0 63.1 63.2 "Aetiology of cancer in Asia". Asian Pacific Journal of Cancer Prevention 9 (3): 371–80. 2008. PMID 18990005. 
  64. "Epidemiology of Stomach Cancer". Cancer Epidemiology. Methods in Molecular Biology. 472. 2009. pp. 467–77. doi:10.1007/978-1-60327-492-0_23. ISBN 978-1-60327-491-3. 
  65. "Cancer Mortality Among Japanese Issei and Nisei of California". Cancer 18 (5): 656–64. May 1965. doi:10.1002/1097-0142(196505)18:5<656::AID-CNCR2820180515>3.0.CO;2-3. PMID 14278899. 
  66. Moore, Patrick S.; Chang, Yuan (2010-11-24). "Why do viruses cause cancer? Highlights of the first century of human tumour virology". Nature Reviews Cancer (Springer Science and Business Media LLC) 10 (12): 878–889. doi:10.1038/nrc2961. ISSN 1474-175X. PMID 21102637. 
  67. "Infectious agents and cancer: criteria for a causal relation". Seminars in Cancer Biology 14 (6): 453–71. December 2004. doi:10.1016/j.semcancer.2004.06.009. PMID 15489139. 
  68. "HPV-associated diseases". Clinics in Dermatology 32 (2): 227–34. 2014. doi:10.1016/j.clindermatol.2013.08.007. PMID 24559558. 
  69. "Chronic bacterial and parasitic infections and cancer: a review". Journal of Infection in Developing Countries 4 (5): 267–81. June 2010. doi:10.3855/jidc.819. PMID 20539059. 
  70. 70.0 70.1 "Radiation" (in en). National Cancer Institute. 29 April 2015. 
  71. 71.0 71.1 71.2 "Sunlight" (in en). National Cancer Institute. 29 April 2015. 
  72. "Cancer prevention". 
  73. 73.0 73.1 73.2 73.3 73.4 "Chapter 14: Ionizing Radiation". Cancer medicine (6th ed.). Hamilton, Ont: B.C. Decker. 2000. ISBN 978-1-55009-113-7. 
  74. "Computed tomography—an increasing source of radiation exposure". The New England Journal of Medicine 357 (22): 2277–84. November 2007. doi:10.1056/NEJMra072149. PMID 18046031. 
  75. 75.0 75.1 "15. Ultraviolet Radiation Carcinogenesis". Holland-Frei Cancer Medicine (5th ed.). Hamilton, Ontario: B.C. Decker. 2000. ISBN 978-1-55009-113-7. Retrieved 31 January 2011. 
  76. "IARC classifies radiofrequency electromagnetic fields as possibly carcinogenic to humans". 
  77. "Electromagnetic Fields and Cancer" (in en). National Cancer Institute. 7 January 2019. 
  78. "Cell Phones and Cancer Risk – National Cancer Institute". 8 May 2013. 
  79. 79.0 79.1 "Genome-wide association studies: how predictable is a person's cancer risk?". Expert Review of Anticancer Therapy 9 (4): 389–92. April 2009. doi:10.1586/era.09.12. PMID 19374592. 
  80. "Colorectal cancer". Lancet 375 (9719): 1030–47. March 2010. doi:10.1016/S0140-6736(10)60353-4. PMID 20304247. 
  81. Kampman, E. (2007). "A First-Degree Relative with Colorectal Cancer: What Are We Missing?". Cancer Epidemiology, Biomarkers & Prevention 16 (1): 1–3. doi:10.1158/1055-9965.EPI-06-0984. ISSN 1055-9965. PMID 17220324. 
  82. "Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium". European Journal of Cancer 48 (13): 1957–68. September 2012. doi:10.1016/j.ejca.2012.01.038. PMID 22436981. 
  83. "Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis". International Journal of Cancer 107 (5): 797–803. December 2003. doi:10.1002/ijc.11466. PMID 14566830. 
  84. Singletary, S. Eva (2003). "Rating the Risk Factors for Breast Cancer". Annals of Surgery 237 (4): 474–82. doi:10.1097/01.SLA.0000059969.64262.87. ISSN 0003-4932. PMID 12677142. 
  85. "Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk". The Lancet. Oncology 12 (8): 785–94. August 2011. doi:10.1016/S1470-2045(11)70154-1. PMID 21782509. 
  86. 86.0 86.1 86.2 86.3 86.4 "Chapter 16: Physical Carcinogens". Holland-Frei Cancer Medicine (5th ed.). Hamilton, Ontario: B.C. Decker. 2000. ISBN 978-1-55009-113-7. Retrieved 31 January 2011. 
  87. 87.0 87.1 87.2 87.3 87.4 87.5 87.6 Gaeta, John F (2000). "Chapter 17: Trauma and Inflammation". Holland-Frei Cancer Medicine (5th ed.). Hamilton, Ontario: B.C. Decker. ISBN 978-1-55009-113-7. Retrieved 27 January 2011. 
  88. "Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability". Carcinogenesis 30 (7): 1073–81. July 2009. doi:10.1093/carcin/bgp127. PMID 19468060. 
  89. "Interaction of tumor cells with the microenvironment". Cell Communication and Signaling 9 (18): 18. September 2011. doi:10.1186/1478-811X-9-18. PMID 21914164. 
  90. "Molecular pathways linking inflammation and cancer". Current Molecular Medicine 10 (4): 369–73. June 2010. doi:10.2174/156652410791316968. PMID 20455855. 
  91. "Inflammation and cancer: the oncogene-driven connection". Cancer Letters 267 (2): 262–70. August 2008. doi:10.1016/j.canlet.2008.03.060. PMID 18502035. 
  92. 92.0 92.1 92.2 92.3 92.4 92.5 92.6 92.7 92.8 92.9 "Chapter 13: Hormones and the Etiology of Cancer". Holland-Frei Cancer Medicine (5th ed.). Hamilton, Ontario: B.C. Decker. 2000. ISBN 978-1-55009-113-7. Retrieved 27 January 2011. 
  93. "Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis". International Journal of Cancer 124 (10): 2416–29. May 2009. doi:10.1002/ijc.24202. PMID 19142965. 
  94. "Association Between Coeliac Disease and Risk of Any Malignancy and Gastrointestinal Malignancy: A Meta-Analysis". Medicine 94 (38): e1612. September 2015. doi:10.1097/MD.0000000000001612. PMID 26402826. 
  95. "Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment". World Journal of Gastroenterology 22 (20): 4794–801. May 2016. doi:10.3748/wjg.v22.i20.4794. PMID 27239106. 
  96. "Oncogenes and cancer". The New England Journal of Medicine 358 (5): 502–11. January 2008. doi:10.1056/NEJMra072367. PMID 18234754. 
  97. "Two genetic hits (more or less) to cancer". Nature Reviews. Cancer 1 (2): 157–62. November 2001. doi:10.1038/35101031. PMID 11905807. 
  98. "Hypoxia and defective apoptosis drive genomic instability and tumorigenesis". Genes & Development 18 (17): 2095–107. September 2004. doi:10.1101/gad.1204904. PMID 15314031. 
  99. "Cancer as an evolutionary and ecological process". Nature Reviews. Cancer 6 (12): 924–35. December 2006. doi:10.1038/nrc2013. PMID 17109012. 
  100. "Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?". Nature Reviews. Cancer 6 (2): 107–16. February 2006. doi:10.1038/nrc1799. PMID 16491070. 
  101. "Epigenetic modifications in cancer". Clinical Genetics 81 (4): 303–11. April 2012. doi:10.1111/j.1399-0004.2011.01809.x. PMID 22082348. 
  102. "Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma". Molecular and Cellular Biology 23 (7): 2225–38. April 2003. doi:10.1128/MCB.23.7.2225-2238.2003. PMID 12640109. /
  103. "Epigenetics Offer New Horizons for Colorectal Cancer Prevention". Current Colorectal Cancer Reports 8 (1): 66–81. March 2012. doi:10.1007/s11888-011-0116-z. PMID 22389639. 
  104. "Mutator pathways unleashed by epigenetic silencing in human cancer". Mutagenesis 22 (4): 247–53. July 2007. doi:10.1093/mutage/gem009. PMID 17412712. 
  105. "Epigenetic changes of DNA repair genes in cancer". Journal of Molecular Cell Biology 3 (1): 51–8. February 2011. doi:10.1093/jmcb/mjq053. PMID 21278452. 
  106. "Epigenetic field defects in progression to cancer". World Journal of Gastrointestinal Oncology 5 (3): 43–49. March 2013. doi:10.4251/wjgo.v5.i3.43. PMID 23671730. 
  107. "Elevated levels of mutation in multiple tissues of mice deficient in the DNA mismatch repair gene Pms2". Proceedings of the National Academy of Sciences of the United States of America 94 (7): 3122–27. April 1997. doi:10.1073/pnas.94.7.3122. PMID 9096356. Bibcode1997PNAS...94.3122N. 
  108. "Differing patterns of genetic instability in mice deficient in the mismatch repair genes Pms2, Mlh1, Msh2, Msh3 and Msh6". Carcinogenesis 27 (12): 2402–08. December 2006. doi:10.1093/carcin/bgl079. PMID 16728433. 
  109. "Disruption of Brca2 increases the spontaneous mutation rate in vivo: synergism with ionizing radiation". EMBO Reports 3 (3): 255–60. March 2002. doi:10.1093/embo-reports/kvf037. PMID 11850397. 
  110. "Bloom's syndrome. I. Genetical and clinical observations in the first twenty-seven patients". American Journal of Human Genetics 21 (2): 196–227. March 1969. PMID 5770175. 
  111. Lee, Jeannie T, ed (August 2008). "Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island". PLOS Genetics 4 (8): e1000155. doi:10.1371/journal.pgen.1000155. PMID 18704159. 
  112. "DNA damage, homology-directed repair, and DNA methylation". PLOS Genetics 3 (7): e110. July 2007. doi:10.1371/journal.pgen.0030110. PMID 17616978. 
  113. "Li-fraumeni syndrome". Genes & Cancer 2 (4): 475–84. April 2011. doi:10.1177/1947601911413466. PMID 21779515. 
  114. "Human cancer syndromes: clues to the origin and nature of cancer". Science 278 (5340): 1043–50. November 1997. doi:10.1126/science.278.5340.1043. PMID 9353177. Bibcode1997Sci...278.1043F. 
  115. "Cancer genome landscapes". Science 339 (6127): 1546–58. March 2013. doi:10.1126/science.1235122. PMID 23539594. Bibcode2013Sci...339.1546V. 
  116. 116.0 116.1 "Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review)". Oncology Letters 4 (6): 1151–1157. 2012. doi:10.3892/ol.2012.928. PMID 23226794. 
  117. "Cancer as a metabolic disease". Nutrition & Metabolism 7: 7. 2010. doi:10.1186/1743-7075-7-7. PMID 20181022. 
  118. "The promise and peril of targeting cell metabolism for cancer therapy". Cancer Immunology, Immunotherapy 69 (2): 255–261. 2020. doi:10.1007/s00262-019-02432-7. PMID 31781842. 
  119. "The emerging role of targeting cancer metabolism for cancer therapy". Tumor Biology 42 (10): 1010428320965284. 2020. doi:10.1177/1010428320965284. PMID 33028168. 
  120. "The Emerging Hallmarks of Cancer Metabolism". Cell Metabolism 23 (1): 27–47. 2016. doi:10.1016/j.cmet.2015.12.006. PMID 26771115. 
  121. "Metabolic Adaptations in Cancer Stem Cells". Frontiers in Oncology 10: 1010. 2020. doi:10.3389/fonc.2020.01010. PMID 32670883. 
  122. "Cancer Screening Guidelines | Detecting Cancer Early" (in en). American Cancer Society. 14 March 2022. 
  123. Connolly, James L.; Schnitt, Stuart J.; Wang, Helen H.; Longtine, Janina A.; Dvorak, Ann; Dvorak, Harold F. (2003). "Role of the Surgical Pathologist in the Diagnosis and Management of the Cancer Patient". in Holland, James F.; Frei, Emil; Kufe, Donald W.. Holland-Frei Cancer Medicine (6 ed.). Hamilton (ON): BC Decker. ISBN 9781550092134. 
  124. "Psychosocial interventions to improve quality of life and emotional wellbeing for recently diagnosed cancer patients". The Cochrane Database of Systematic Reviews 11 (11): CD007064. November 2012. doi:10.1002/14651858.cd007064.pub2. PMID 23152241. 
  125. Pearson, Catherine (10 January 2024). "Why Some People Keep Serious Illnesses Private". The New York Times. 
  126. Varricchio, Claudette G. (2004). A cancer source book for nurses. Boston: Jones and Bartlett Publishers. p. 229. ISBN 978-0-7637-3276-9. 
  127. Image by Mikael Häggström, MD. Source for findings: Caroline I.M. Underwood, M.D., Carolyn Glass, M.D., Ph.D.. "Lung - Small cell carcinoma".  Last author update: 20 September 2022
  128. 128.0 128.1 128.2 Tran, Khanh BaoExpression error: Unrecognized word "et". (20 August 2022). "The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019" (in English). The Lancet 400 (10352): 563–591. doi:10.1016/S0140-6736(22)01438-6. ISSN 0140-6736. PMID 35988567. 
  129. "Cancer prevention: 7 steps to reduce your risk". Mayo Clinic. 27 September 2008. 
  130. "Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors". Lancet 366 (9499): 1784–93. November 2005. doi:10.1016/S0140-6736(05)67725-2. PMID 16298215. 
  131. "Substantial contribution of extrinsic risk factors to cancer development". Nature 529 (7584): 43–7. January 2016. doi:10.1038/nature16166. PMID 26675728. Bibcode2016Natur.529...43W. 
  132. "Cancer". 
  133. Heidary, Fatemeh; Rahimi, Abolfazl; Gharebaghi, Reza (2013). "Poverty as a risk factor in human cancers". Iranian Journal of Public Health 42 (3): 341–343. ISSN 2251-6085. PMID 23641414. 
  134. 134.0 134.1 "Diet and cancer". Swiss Medical Weekly 141: w13250. September 2011. doi:10.4414/smw.2011.13250. PMID 21904992. 
  135. "Diet, obesity and breast cancer: an update". Frontiers in Bioscience 4 (1): 90–108. January 2012. doi:10.2741/253. PMID 22202045. 
  136. "Fruit and vegetables and cancer risk". British Journal of Cancer 104 (1): 6–11. January 2011. doi:10.1038/sj.bjc.6606032. PMID 21119663. 
  137. "Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies". BMJ 349: g4490. July 2014. doi:10.1136/bmj.g4490. PMID 25073782. 
  138. "Coffee consumption and risk of liver cancer: a meta-analysis". Gastroenterology 132 (5): 1740–5. May 2007. doi:10.1053/j.gastro.2007.03.044. PMID 17484871. 
  139. "Well-done meat intake, heterocyclic amine exposure, and cancer risk". Nutrition and Cancer 61 (4): 437–46. 2009. doi:10.1080/01635580802710741. PMID 19838915. 
  140. "Meat and cancer". Meat Science 84 (2): 308–13. February 2010. doi:10.1016/j.meatsci.2009.06.032. PMID 20374790. 
  141. Staff (26 October 2015). "World Health Organization – IARC Monographs evaluate consumption of red meat and processed meat". International Agency for Research on Cancer. 
  142. Hauser, Christine (26 October 2015). "W.H.O. Report Links Some Cancers With Processed or Red Meat". The New York Times. 
  143. Holland Chp.33
  144. "Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force". Annals of Internal Medicine 146 (5): 376–89. March 2007. doi:10.7326/0003-4819-146-5-200703060-00010. PMID 17339623. 
  145. "Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials". Lancet 377 (9759): 31–41. January 2011. doi:10.1016/S0140-6736(10)62110-1. PMID 21144578. 
  146. "Chemoprevention of colorectal cancer: systematic review and economic evaluation". Health Technology Assessment 14 (32): 1–206. June 2010. doi:10.3310/hta14320. PMID 20594533. 
  147. "Chemoprevention of breast cancer". American Journal of Health-System Pharmacy 65 (23): 2221–28. December 2008. doi:10.2146/ajhp070663. PMID 19020189. 
  148. "Five-alpha-reductase Inhibitors for prostate cancer prevention". The Cochrane Database of Systematic Reviews (2): CD007091. April 2008. doi:10.1002/14651858.CD007091. PMID 18425978. 
  149. "Vitamins and minerals: not for cancer or cardiovascular prevention". Prescrire International 19 (108): 182. August 2010. PMID 20939459. 
  150. "Prospective study of predictors of vitamin D status and cancer incidence and mortality in men". Journal of the National Cancer Institute 98 (7): 451–59. April 2006. doi:10.1093/jnci/djj101. PMID 16595781. 
  151. "Vitamin D Has Role in Colon Cancer Prevention". 
  152. "Vitamin D, sunlight and cancer connection". Anti-Cancer Agents in Medicinal Chemistry 13 (1): 70–82. January 2013. doi:10.2174/187152013804487308. PMID 23094923. 
  153. "Vitamin D status and cancer incidence and mortality: something new under the sun". Journal of the National Cancer Institute 98 (7): 428–30. April 2006. doi:10.1093/jnci/djj127. PMID 16595770. 
  154. 154.0 154.1 "The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis". The Lancet. Diabetes & Endocrinology 2 (4): 307–320. April 2014. doi:10.1016/S2213-8587(13)70212-2. PMID 24703049. 
  155. "Vitamin D supplementation for prevention of mortality in adults". The Cochrane Database of Systematic Reviews 1 (1): CD007470. January 2014. doi:10.1002/14651858.cd007470.pub3. PMID 24414552. 
  156. Minna, John D, ed (2011). "Vitamin A and retinoid derivatives for lung cancer: a systematic review and meta analysis". PLOS ONE 6 (6): e21107. doi:10.1371/journal.pone.0021107. PMID 21738614. Bibcode2011PLoSO...621107F. 
  157. "Folic acid for the prevention of colorectal adenomas: a randomized clinical trial". JAMA 297 (21): 2351–2359. June 2007. doi:10.1001/jama.297.21.2351. PMID 17551129. 
  158. "Selenium for preventing cancer". The Cochrane Database of Systematic Reviews 1 (1): CD005195. January 2018. doi:10.1002/14651858.CD005195.pub4. PMID 29376219. 
  159. 159.0 159.1 159.2 "Cancer Vaccine Fact Sheet". NCI. 8 June 2006. 
  160. 160.0 160.1 "Cancer prevention in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013". The Lancet. Oncology 14 (12): e497–507. November 2013. doi:10.1016/S1470-2045(13)70350-4. PMID 24176569. 
  161. 161.0 161.1 161.2 "Cancer Screening Overview (PDQ®)–Patient Version". National Cancer Institute. 13 January 2010. 
  162. 162.0 162.1 162.2 Wilson JMG, Jungner G. (1968) Principles and practice of screening for disease. Geneva: World Health Organization. Public Health Papers, No. 34.
  163. "Screening for Cervical Cancer". 2003. 
  164. "Screening for Colorectal Cancer". 2008. 
  165. "Screening for Skin Cancer". 2009. 
  166. "Screening for Oral Cancer". 2004. 
  167. "Lung Cancer Screening". 2004. 
  168. "Screening for Prostate Cancer". 2008. 
  169. "Screening for Bladder Cancer". 2004. 
  170. "Screening for Testicular Cancer". 2004. 
  171. "Screening for Ovarian Cancer". 2004. 
  172. "Screening for Pancreatic Cancer". 2004. 
  173. "Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force". Annals of Internal Medicine (United States Preventive Services Task Force) 155 (11): 762–71. December 2011. doi:10.7326/0003-4819-155-11-201112060-00375. PMID 21984740. 
  174. "Screening for Breast Cancer". 2009. 
  175. "Screening for breast cancer with mammography". The Cochrane Database of Systematic Reviews 2013 (6): CD001877. June 2013. doi:10.1002/14651858.CD001877.pub5. PMID 23737396. 
  176. 176.0 176.1 "The clinical management of BRCA1 and BRCA2 mutation carriers". Current Oncology Reports 10 (1): 47–53. January 2008. doi:10.1007/s11912-008-0008-9. PMID 18366960. 
  177. "Principles of cytotoxic chemotherapy". Medicine 36 (1): 19–23. 2008. doi:10.1016/j.mpmed.2007.10.003. 
  178. Emil Frei, I. I. I.; Eder, Joseph Paul (2003) (in en). Combination Chemotherapy. Retrieved 4 April 2020. 
  179. "Combination versus sequential single agent chemotherapy for metastatic breast cancer". The Cochrane Database of Systematic Reviews 2021 (12): CD008792. December 2013. doi:10.1002/14651858.CD008792.pub2. PMID 24347031. 
  180. "Targeted Cancer Therapies". National Cancer Institute. 26 February 2018. 
  181. 181.0 181.1 Holland Chp. 40
  182. "Diffuse large B-cell lymphoma: current treatment approaches". Oncology 26 (5): 488–95. May 2012. PMID 22730604. 
  183. "Follicular lymphoma: 2012 update on diagnosis and management". American Journal of Hematology 87 (10): 988–95. October 2012. doi:10.1002/ajh.23313. PMID 23001911. 
  184. "The present and future management of malignant brain tumours: surgery, radiotherapy, chemotherapy". Journal of Neurology, Neurosurgery, and Psychiatry 75 (Suppl 2): ii24–30. June 2004. doi:10.1136/jnnp.2004.040535. PMID 15146036. 
  185. "Non-melanoma skin cancer". Lancet 375 (9715): 673–85. February 2010. doi:10.1016/S0140-6736(09)61196-X. PMID 20171403. 
  186. Vitale, Ilio; Galluzzi, Lorenzo; Castedo, Maria; Kroemer, Guido (June 2011). "Mitotic catastrophe: a mechanism for avoiding genomic instability" (in en). Nature Reviews Molecular Cell Biology 12 (6): 385–392. doi:10.1038/nrm3115. ISSN 1471-0072. PMID 21527953. 
  187. CK Bomford, IH Kunkler, J Walter. Walter and Miller's Textbook of Radiation therapy (6th Ed), p311
  188. Prince, Jim McMorran, Damian Crowther, Stew McMorran, Steve Youngmin, Ian Wacogne, Jon Pleat, Clive. "tumour radiosensitivity – General Practice Notebook". 
  189. Tidy, Colin (23 December 2015). "Radiotherapy". Patient UK.  Last Checked: 23 December 2015
  190. "Advances in kilovoltage x-ray beam dosimetry". Physics in Medicine and Biology 59 (6): R183–231. March 2014. doi:10.1088/0031-9155/59/6/r183. PMID 24584183. Bibcode2014PMB....59R.183H. 
  191. 191.0 191.1 Holland Chp. 41
  192. "Radiation Therapy for Brain Metastases: A Systematic Review" (in en). 2019-08-13. 
  193. 193.0 193.1 193.2 193.3 193.4 American Society of Clinical Oncology. "Five Things Physicians and Patients Should Question". Choosing Wisely: An Initiative of the ABIM Foundation. Retrieved 14 August 2012. 
  194. * The American Society of Clinical Oncology made this recommendation based on various cancers. See American Society of Clinical Oncology. "Five Things Physicians and Patients Should Question". Choosing Wisely: An Initiative of the ABIM Foundation. Retrieved 14 August 2012. 
  195. "NCCN Guidelines". 
  196. "Clinical Practice Guidelines for Quality Palliative Care". The National Consensus Project for Quality Palliative Care (NCP). 
  197. "Palliative care. Clinical practice guidelines in oncology". Journal of the National Comprehensive Cancer Network 4 (8): 776–818. September 2006. doi:10.6004/jnccn.2006.0068. PMID 16948956. 
  198. "Immunotherapy: past, present and future". Nature Medicine 9 (3): 269–77. March 2003. doi:10.1038/nm0303-269. PMID 12612576. 
  199. "Lasers in Cancer Treatment". National Institutes of Health, National Cancer Institute. 13 September 2011.  This article incorporates text from this source, which is in the public domain.
  200. "Complementary and alternative therapies for cancer". The Oncologist 9 (1): 80–89. 2004. doi:10.1634/theoncologist.9-1-80. PMID 14755017. 
  201. What Is CAM? National Center for Complementary and Alternative Medicine. Retrieved 3 February 2008.
  202. "Alternative cancer cures: "unproven" or "disproven"?". CA: A Cancer Journal for Clinicians 54 (2): 110–18. 2004. doi:10.3322/canjclin.54.2.110. PMID 15061600. 
  203. "Three measures of cancer mortality". 
  204. Tammela, Tuomas; Sage, Julien (2020). "Investigating Tumor Heterogeneity in Mouse Models". Annual Review of Cancer Biology 4 (1): 99–119. doi:10.1146/annurev-cancerbio-030419-033413. PMID 34164589. 
  205. World Cancer Report 2014. World Health Organization. 2014. p. 22. ISBN 978-92-832-0429-9. 
  206. 206.0 206.1 Rheingold, Susan; Neugut, Alfred; Meadows, Anna (2003). "156: Secondary Cancers: Incidence, Risk Factors, and Management". Holland-Frei Cancer Medicine (6th ed.). Hamilton, Ont: BC Decker. p. 2399. ISBN 978-1-55009-213-4. 
  207. "Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008". Health and Quality of Life Outcomes 7: 102. December 2009. doi:10.1186/1477-7525-7-102. PMID 20030832. 
  208. 208.0 208.1 208.2 "Parenteral anticoagulation in ambulatory patients with cancer". The Cochrane Database of Systematic Reviews 2021 (9): CD006652. September 2017. doi:10.1002/14651858.CD006652.pub5. PMID 28892556. 
  209. Radha G., Lopus M. (2021) The spontaneous remission of cancer: Current insights and therapeutic significance. Translational Oncology. 14 (9):101166, doi:10.1016/j.tranon.2021.101166
  210. "Cancer death rates". 
  211. 211.0 211.1 "Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018". 
  212. 212.0 212.1 "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet 380 (9859): 2095–128. December 2012. doi:10.1016/S0140-6736(12)61728-0. PMID 23245604. PMC 10790329. 
  213. 213.0 213.1 Coleman, William B.; Rubinas, Tara C. (2009). "4". Molecular Pathology: The Molecular Basis of Human Disease. Amsterdam: Elsevier Academic Press. p. 66. ISBN 978-0-12-374419-7. [yes|permanent dead link|dead link}}]
  214. Johnson, George (28 December 2010). "Unearthing Prehistoric Tumors, and Debate". The New York Times. 
  215. "Immunosenescence and cancer". Critical Reviews in Oncology/Hematology 75 (2): 165–72. August 2010. doi:10.1016/j.critrevonc.2010.06.012. PMID 20656212. 
  216. "The Preventable Causes of Cancer". Molecular biology of the cell (4th ed.). New York: Garland Science. 2002. ISBN 978-0-8153-4072-0. "A certain irreducible background incidence of cancer is to be expected regardless of circumstances: mutations can never be absolutely avoided, because they are an inescapable consequence of fundamental limitations on the accuracy of DNA replication, as discussed in Chapter 5. If a human could live long enough, it is inevitable that at least one of his or her cells would eventually accumulate a set of mutations sufficient for cancer to develop." 
  217. "Relationships between cancer and aging: a multilevel approach". Biogerontology 10 (4): 323–38. August 2009. doi:10.1007/s10522-008-9209-8. PMID 19156531. 
  218. "How ageing processes influence cancer". Nature Reviews. Cancer 13 (5): 357–65. May 2013. doi:10.1038/nrc3497. PMID 23612461. 
  219. Schottenfeld, David; Fraumeni, Joseph F. (24 August 2006). Cancer Epidemiology and Prevention. Oxford University Press. p. 977. ISBN 978-0-19-974797-9. 
  220. Bostwick, David G.; Eble, John N. (2007). Urological Surgical Pathology. St. Louis: Mosby. p. 468. ISBN 978-0-323-01970-5. 
  221. 221.0 221.1 "Epidemiology of childhood cancer". Cancer Treatment Reviews 36 (4): 277–85. June 2010. doi:10.1016/j.ctrv.2010.02.003. PMID 20231056. 
  222. 222.0 222.1 "Childhood and adolescent cancer statistics, 2014". CA: A Cancer Journal for Clinicians 64 (2): 83–103. January 2014. doi:10.3322/caac.21219. PMID 24488779. 
  223. "Interpreting cancer trends". Annals of the New York Academy of Sciences 1076 (1): 29–53. September 2006. doi:10.1196/annals.1371.048. PMID 17119192. Bibcode2006NYASA1076...29W. 
  224. 224.0 224.1 224.2 224.3 224.4 224.5 "A note from history: landmarks in history of cancer, part 1". Cancer 117 (5): 1097–102. March 2011. doi:10.1002/cncr.25553. PMID 20960499. 
  225. Paul of Aegina, 7th century AD, quoted in Moss, Ralph W. (2004). "Galen on Cancer". CancerDecisions.  Referenced from Michael Shimkin, Contrary to Nature, Washington, DC: Superintendent of Document, DHEW Publication No. (NIH) 79–720, p. 35.
  226. Majno, Guido; Joris, Isabelle (12 August 2004). Cells, Tissues, and Disease : Principles of General Pathology: Principles of General Pathology. Oxford University Press. ISBN 978-0-19-974892-1. Retrieved 11 September 2013. 
  227. 227.0 227.1 "A note from history: landmarks in history of cancer, part 2". Cancer 117 (12): 2811–20. June 2011. doi:10.1002/cncr.25825. PMID 21656759. 
  228. Yalom, Marilyn (1998). A history of the breast (1 ed.). New York: Ballantine Books. ISBN 978-0-679-43459-7. 
  229. "A note from history: landmarks in history of cancer, part 3". Cancer 118 (4): 1155–68. February 2012. doi:10.1002/cncr.26320. PMID 21751192. 
  230. "Campbell De Morgan's 'Observations on cancer', and their relevance today". Journal of the Royal Society of Medicine 95 (6): 296–299. June 2002. doi:10.1177/014107680209500609. PMID 12042378. 
  231. Ehrenreich, Barbara (November 2001). "Welcome to Cancerland". Harper's Magazine. ISSN 0017-789X. 
  232. Pozorski, Aimee (20 March 2015). "Confronting the "C" Word: Cancer and Death in Philip Roth's Fiction" (in en). Philip Roth Studies 11 (1): 105–123. doi:10.5703/philrothstud.11.1.105. ISSN 1940-5278. Retrieved 13 April 2020. 
  233. Wollaston, Sam (4 May 2015). "The C-Word review – a wonderful testament to a woman who faced cancer with honesty, verve and wit". The Guardian. 
  234. "Avoiding the 'C' Word for Low-Risk Thyroid Cancer". Medscape. 
  235. "The C word: how we react to cancer today" (in en-gb). 
  236. 236.0 236.1 236.2 236.3 Chochinov, Harvey Max; Breitbart, William (2009) (in en). Handbook of Psychiatry in Palliative Medicine. Oxford University Press. p. 196. ISBN 978-0-19-530107-6. 
  237. Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. ISBN 978-1-4160-2999-1. 
  238. "Skin cancers". World Health Organization. 
  239. McCulley, Michelle; Greenwell, Pamela (2007). Molecular therapeutics: 21st-century medicine. London: J. Wiley. p. 207. ISBN 978-0-470-01916-0. [yes|permanent dead link|dead link}}]
  240. Low, Graham; Cameron, Lynne (1999). "10". Researching and Applying Metaphor. Cambridge University Press. ISBN 978-0-521-64964-3. 
  241. Sulik, Gayle A. (2010). Pink Ribbon Blues: How Breast Cancer Culture Undermines Women's Health. Oxford University Press. pp. 78–89. ISBN 978-0-19-974993-5. 
  242. 242.0 242.1 242.2 Olson, James S. (2005). Bathsheba's Breast: Women, Cancer, and History. JHU Press. pp. 145–70. ISBN 978-0-8018-8064-3. OCLC 186453370. 
  243. 243.0 243.1 243.2 243.3 Ehrenreich, Barbara (2009). Bright-sided: How the Relentless Promotion of Positive Thinking Has Undermined America. Henry Holt and Company. pp. 15–44. ISBN 978-0-8050-8749-9. 
  244. Huff, Charlotte (24 September 2013). "A Sick Stigma: Why are cancer patients blamed for their illness?". Slate. 
  245. "Economic Impact of Cancer". 3 January 2018. 
  246. "The economics of cancer care in the UK". Lancet Oncology 5 (9): 568–74. 2004. doi:10.1016/S1470-2045(04)01569-4. PMID 15337487. 
  247. "Projections of the cost of cancer care in the United States: 2010–2020". Journal of the National Cancer Institute 103 (2): 117–28. 2011. doi:10.1093/jnci/djq495. PMID 21228314. 
  248. "The cost and burden of cancer in the European Union 1995–2014". European Journal of Cancer 66 (Oct): 162–70. 2016. doi:10.1016/j.ejca.2016.06.022. PMID 27589247. 
  249. 249.0 249.1 "The cost of cancer in Europe 2018". European Journal of Cancer 129 (Apr): 41–49. 2020. doi:10.1016/j.ejca.2020.01.011. PMID 32120274. 
  250. "Economic burden of cancer across the European Union: a population-based cost analysis". Lancet Oncology 14 (12): 1165–74. 2013. doi:10.1016/S1470-2045(13)70442-X. PMID 24131614. 
  251. 251.0 251.1 U.S. Equal Employment Opportunity Commission. "Questions & Answers about Cancer in the Workplace and the Americans with Disabilities Act (ADA)."
  252. "Men Leave: Separation and Divorce Far More Common when the Wife is the Patient". 
  253. "Men more likely than women to leave partner with cancer". Reuters. 12 November 2009. 
  254. "What Is Cancer?". National Cancer Institute. 17 September 2007. 
  255. "Cancer Fact Sheet". Agency for Toxic Substances & Disease Registry. 30 August 2002. 
  256. Wanjek, Christopher (16 September 2006). "Exciting New Cancer Treatments Emerge Amid Persistent Myths". 
  257. "Cutting off cancer's supply lines". Nature 458 (7239): 686–87. April 2009. doi:10.1038/458686b. PMID 19360048. 
  258. "Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale". Trends in Molecular Medicine 16 (3): 122–32. March 2010. doi:10.1016/j.molmed.2010.01.004. PMID 20189876. 
  259. "Repurposing Strategies for Therapeutics". Pharmaceutical Medicine 24 (3): 151–59. 2010. doi:10.1007/BF03256811. 
  260. "Drug-Diagnostic Co-Development in Cancer". Pharmaceutical Medicine 24 (6): 363–75. 2010. doi:10.1007/BF03256837. 
  261. Begley, Sharon (16 September 2008). "Rethinking the War on Cancer". 
  262. Kolata, Gina (23 April 2009). "Advances Elusive in the Drive to Cure Cancer". The New York Times. 
  263. "Rescuing US biomedical research from its systemic flaws". Proceedings of the National Academy of Sciences of the United States of America 111 (16): 5773–77. 2014. doi:10.1073/pnas.1404402111. PMID 24733905. Bibcode2014PNAS..111.5773A. 
  264. Kolata, Gina (23 April 2009). "Advances Elusive in the Drive to Cure Cancer". The New York Times. 
  265. Kolata, Gina (27 June 2009). "Grant System Leads Cancer Researchers to Play It Safe". The New York Times. 
  266. "Young, talented and fed-up: scientists tell their stories". Nature 538 (7626): 446–49. 2016. doi:10.1038/538446a. PMID 27786221. Bibcode2016Natur.538..446P. 
  267. "Opinion | I'm an oncologist. My worst fears about Covid and cancer are coming true". 12 February 2021. 
  268. "Don't sacrifice cancer care to COVID". 13 January 2021. 
  269. 269.0 269.1 269.2 269.3 269.4 269.5 Yarbro, Connie Henke; Wujcik, Debra; Gobel, Barbara Holmes (2010). Cancer Nursing: Principles and Practice. Jones & Bartlett Learning. pp. 901–905. ISBN 978-0-7637-6357-2. 
  270. Thamm, Douglas (March 2009). "How companion animals contribute to the fight against cancer in humans". Veterinaria Italiana 54 (1): 111–20. PMID 20391394. Retrieved 18 July 2014. 
  271. Vincze, Orsolya; Colchero, Fernando; Lemaître, Jean-Francois; Conde, Dalia A.; Pavard, Samuel; Bieuville, Margaux; Urrutia, Araxi O.; Ujvari, Beata et al. (13 January 2022). "Cancer risk across mammals". Nature 601 (7892): 263–267. doi:10.1038/s41586-021-04224-5. PMID 34937938. Bibcode2022Natur.601..263V. 
  272. "Clonal origin and evolution of a transmissible cancer". Cell 126 (3): 477–87. August 2006. doi:10.1016/j.cell.2006.05.051. PMID 16901782. 

Further reading

External links

External resources


| name = Tumors
| title = Overview of tumors, cancer and oncology (C00–D48, 140–239)
| state = uncollapsed
| listclass = hlist
| group1 = Conditions

| list1 =